WO2022247942A1 - 一种稠合吡啶环衍生物的可药用盐、晶型及其制备方法 - Google Patents
一种稠合吡啶环衍生物的可药用盐、晶型及其制备方法 Download PDFInfo
- Publication number
- WO2022247942A1 WO2022247942A1 PCT/CN2022/095748 CN2022095748W WO2022247942A1 WO 2022247942 A1 WO2022247942 A1 WO 2022247942A1 CN 2022095748 W CN2022095748 W CN 2022095748W WO 2022247942 A1 WO2022247942 A1 WO 2022247942A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- salt
- crystal form
- compound
- ray powder
- Prior art date
Links
- 239000013078 crystal Chemical group 0.000 title claims abstract description 153
- 238000002360 preparation method Methods 0.000 title claims abstract description 56
- 150000003839 salts Chemical group 0.000 title claims abstract description 39
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 233
- 159000000000 sodium salts Chemical class 0.000 claims abstract description 77
- 239000004381 Choline salt Substances 0.000 claims abstract description 51
- 235000019417 choline salt Nutrition 0.000 claims abstract description 51
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims abstract description 19
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims abstract description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 10
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 10
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims abstract description 10
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims abstract description 8
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 8
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract description 7
- 229940049920 malate Drugs 0.000 claims abstract description 7
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims abstract description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims abstract description 6
- 229940095064 tartrate Drugs 0.000 claims abstract description 5
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 83
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 71
- 238000002156 mixing Methods 0.000 claims description 30
- 238000001228 spectrum Methods 0.000 claims description 27
- -1 compound choline salt Chemical class 0.000 claims description 24
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 17
- 108090000565 Capsid Proteins Proteins 0.000 claims description 15
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 9
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical group C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 208000035473 Communicable disease Diseases 0.000 claims description 4
- 208000031886 HIV Infections Diseases 0.000 claims description 3
- 208000037357 HIV infectious disease Diseases 0.000 claims description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 3
- 229940121649 protein inhibitor Drugs 0.000 claims description 3
- 239000012268 protein inhibitor Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 150000003248 quinolines Chemical class 0.000 abstract description 40
- 150000002169 ethanolamines Chemical class 0.000 abstract description 6
- 239000000047 product Substances 0.000 description 91
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 75
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 72
- 239000007787 solid Substances 0.000 description 72
- 239000000243 solution Substances 0.000 description 61
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 60
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 54
- 239000000843 powder Substances 0.000 description 53
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 46
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 39
- 239000002904 solvent Substances 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 238000003756 stirring Methods 0.000 description 28
- 238000001035 drying Methods 0.000 description 27
- 238000001914 filtration Methods 0.000 description 26
- 230000000670 limiting effect Effects 0.000 description 25
- 238000005406 washing Methods 0.000 description 25
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 238000004949 mass spectrometry Methods 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 241000725303 Human immunodeficiency virus Species 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000002244 precipitate Substances 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 238000010009 beating Methods 0.000 description 9
- 239000003480 eluent Substances 0.000 description 9
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 8
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 229940075419 choline hydroxide Drugs 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- 238000002411 thermogravimetry Methods 0.000 description 8
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- 239000003643 water by type Substances 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 150000001483 arginine derivatives Chemical class 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 229910001415 sodium ion Inorganic materials 0.000 description 6
- 230000004580 weight loss Effects 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000010926 purge Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 3
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004296 chiral HPLC Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229960003194 meglumine Drugs 0.000 description 3
- 150000003892 tartrate salts Chemical class 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 2
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 241000662429 Fenerbahce Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000798 anti-retroviral effect Effects 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 108010023700 galanin-(1-13)-bradykinin-(2-9)-amide Proteins 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- JFOZKMSJYSPYLN-QHCPKHFHSA-N lifitegrast Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C=2C(=C3CCN(CC3=CC=2Cl)C(=O)C=2C=C3OC=CC3=CC=2)Cl)C(O)=O)=C1 JFOZKMSJYSPYLN-QHCPKHFHSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 150000002688 maleic acid derivatives Chemical class 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 1
- JNPGUXGVLNJQSQ-BGGMYYEUSA-M (e,3r,5s)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)N1C(C(C)C)=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C1 JNPGUXGVLNJQSQ-BGGMYYEUSA-M 0.000 description 1
- VAVHMEQFYYBAPR-ITWZMISCSA-N (e,3r,5s)-7-[4-(4-fluorophenyl)-1-phenyl-2-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(C=2C=CC(F)=CC=2)=CN1C1=CC=CC=C1 VAVHMEQFYYBAPR-ITWZMISCSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- KVSVNRFSKRFPIL-UHFFFAOYSA-N 1-(bromomethyl)-3,5-difluorobenzene Chemical compound FC1=CC(F)=CC(CBr)=C1 KVSVNRFSKRFPIL-UHFFFAOYSA-N 0.000 description 1
- CESUXLKAADQNTB-ZETCQYMHSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](N)=O CESUXLKAADQNTB-ZETCQYMHSA-N 0.000 description 1
- IQTHEAQKKVAXGV-UHFFFAOYSA-N 4-ditert-butylphosphanyl-n,n-dimethylaniline Chemical compound CN(C)C1=CC=C(P(C(C)(C)C)C(C)(C)C)C=C1 IQTHEAQKKVAXGV-UHFFFAOYSA-N 0.000 description 1
- MWVKLRSIDOXBSE-UHFFFAOYSA-N 5-(1-piperidin-4-ylpyrazol-4-yl)-3-(6-pyrrolidin-1-yl-1,3-benzoxazol-2-yl)pyridin-2-amine Chemical compound NC1=NC=C(C2=CN(N=C2)C2CCNCC2)C=C1C(OC1=C2)=NC1=CC=C2N1CCCC1 MWVKLRSIDOXBSE-UHFFFAOYSA-N 0.000 description 1
- 101100481028 Arabidopsis thaliana TGA2 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- QYLRWPLDMZOGEF-UHFFFAOYSA-N BrC1=NC(=C(C2=C1CCC2)Br)C(=O)OCC Chemical compound BrC1=NC(=C(C2=C1CCC2)Br)C(=O)OCC QYLRWPLDMZOGEF-UHFFFAOYSA-N 0.000 description 1
- OCGAUFNWXRDWCW-UHFFFAOYSA-N C1CC2=C(C1)C(=NC(=C2Br)C=O)Br Chemical compound C1CC2=C(C1)C(=NC(=C2Br)C=O)Br OCGAUFNWXRDWCW-UHFFFAOYSA-N 0.000 description 1
- FSTIENFSQUUDCN-UHFFFAOYSA-N C1CC2=C(C1)C(=NC(=C2Br)CO)Br Chemical compound C1CC2=C(C1)C(=NC(=C2Br)CO)Br FSTIENFSQUUDCN-UHFFFAOYSA-N 0.000 description 1
- DGJMHKMYSDYOFP-MRXNPFEDSA-N C=CC(N(CCC1)C[C@@H]1N1N=C(C2=CN(CC(C3=CC=CC=C3)(F)F)N=N2)C2=C(N)N=CN=C12)=O Chemical compound C=CC(N(CCC1)C[C@@H]1N1N=C(C2=CN(CC(C3=CC=CC=C3)(F)F)N=N2)C2=C(N)N=CN=C12)=O DGJMHKMYSDYOFP-MRXNPFEDSA-N 0.000 description 1
- FBVNTMWWICVHIG-UHFFFAOYSA-N CC(C)(C)OC(=O)NC(CC1=CC(=CC(=C1)F)F)C2=C(C3=C(CCC3)C(=N2)Br)Br Chemical compound CC(C)(C)OC(=O)NC(CC1=CC(=CC(=C1)F)F)C2=C(C3=C(CCC3)C(=N2)Br)Br FBVNTMWWICVHIG-UHFFFAOYSA-N 0.000 description 1
- SLENMGMLQCHYGX-UHFFFAOYSA-N CC(C)(C)OC(=O)NC(CC1=CC(=CC(=C1)F)F)C2=C(C3=C(CCC3)C(=N2)C#CC(C)(C)S(=O)(=O)C)Br Chemical compound CC(C)(C)OC(=O)NC(CC1=CC(=CC(=C1)F)F)C2=C(C3=C(CCC3)C(=N2)C#CC(C)(C)S(=O)(=O)C)Br SLENMGMLQCHYGX-UHFFFAOYSA-N 0.000 description 1
- WDBCHSDNXUZUSN-CWWGLNLWSA-N CC(C)(C)[S@](=O)/N=C\C1=C(C2=C(CCC2)C(=N1)Br)Br Chemical compound CC(C)(C)[S@](=O)/N=C\C1=C(C2=C(CCC2)C(=N1)Br)Br WDBCHSDNXUZUSN-CWWGLNLWSA-N 0.000 description 1
- WGKQXPBWWOPCHT-HJLWYHJMSA-N CC(C)(C)[S@](=O)NC(CC1=CC(=CC(=C1)F)F)C2=C(C3=C(CCC3)C(=N2)Br)Br Chemical compound CC(C)(C)[S@](=O)NC(CC1=CC(=CC(=C1)F)F)C2=C(C3=C(CCC3)C(=N2)Br)Br WGKQXPBWWOPCHT-HJLWYHJMSA-N 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- BEXZJJQVPWJPOA-VOTSOKGWSA-N [(e)-hept-2-enyl] 6-methyl-4-(4-nitrophenyl)-2-oxo-3,4-dihydro-1h-pyrimidine-5-carboxylate Chemical compound CCCC\C=C\COC(=O)C1=C(C)NC(=O)NC1C1=CC=C([N+]([O-])=O)C=C1 BEXZJJQVPWJPOA-VOTSOKGWSA-N 0.000 description 1
- HGDWHTASNMRJMP-UHFFFAOYSA-N [1-(hydroxyamino)-1-oxo-5-(3-phenoxyphenyl)pentan-2-yl]phosphonic acid Chemical compound ONC(=O)C(P(O)(O)=O)CCCC1=CC=CC(OC=2C=CC=CC=2)=C1 HGDWHTASNMRJMP-UHFFFAOYSA-N 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- JYVHOGDBFNJNMR-UHFFFAOYSA-N hexane;hydrate Chemical compound O.CCCCCC JYVHOGDBFNJNMR-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940124525 integrase strand transfer inhibitor Drugs 0.000 description 1
- 229940116298 l- malic acid Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- QEQBINKVWYLHGD-BTVCFUMJSA-N methanamine;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound NC.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O QEQBINKVWYLHGD-BTVCFUMJSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- UIUXUFNYAYAMOE-UHFFFAOYSA-N methylsilane Chemical compound [SiH3]C UIUXUFNYAYAMOE-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000004441 surface measurement Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Definitions
- the present disclosure relates to a pharmaceutically acceptable salt, crystal form and preparation method of a fused pyridine ring derivative. Specifically, it provides choline salt, sodium salt, potassium salt, calcium salt, refined Acid, Lysine, Meglumine, Ethanolamine, Bisulfate, Hydrochloride, Tartrate, Maleate, Citrate, Malate, p-Toluenesulfonate and Methanesulfonic Acid salt, and in crystalline form.
- AIDS also known as acquired immunodeficiency syndrome (AIDS)
- HIV human immunodeficiency virus
- CD4 + T lymphocyte function is damaged and destroyed in large quantities, resulting in cellular immune deficiency, and then causing various serious opportunistic infections and tumors.
- HIV acquired immunodeficiency syndrome
- HAART highly active antiretroviral drugs
- NRTIs nucleotide reverse transcription inhibitors
- NRTIs non-nucleotide reverse transcriptase inhibitors
- PIs protease inhibitors
- IPIs integrase strand transfer inhibitors
- HIV-1 type 1 human immunodeficiency virus
- these combination therapies are prone to produce drug-resistant HIV strains, which eventually lead to drug failure, virus escape, and disease progression (Grant, R.M. , Hecht, F.M., Warmerdam, M., JAMA 2002, 288, 181-188-559; Smith, R.J., Okano, J.T., Kahn, J.S., Bodine, E.N., Blower, S., Science 2010, 327, 697-701). Therefore, there is an urgent need to develop new antiretroviral drugs that are active against emerging drug-resistant HIV variants. In particular, the new drugs developed should have a high degree of genetic barriers to drug resistance, and have higher safety and patient compliance than existing drugs.
- WO2021104413 provides a compound as shown in formula I, its chemical name is N-((S)-1-((R)-4-(4-chloro-3-(methanesulfonamide)-1-(2 ,2,2-Trifluoroethyl)-1H-indazol-7-yl)-1-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)-6,7 - Dihydro-5H-cyclopenta[c]pyridin-3-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro -3-(Trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide , the compound has a good inhibitory effect on HIV-1 capsid protein,
- the present disclosure provides pharmaceutically acceptable salts of compounds represented by formula (I), wherein the pharmaceutically acceptable salts are selected from the group consisting of choline salts, sodium salts, potassium salts, calcium salts, arginine salts, lysine salts, glucose Methylamine salt, ethanolamine salt, bisulfate, hydrochloride, tartrate, maleate, citrate, malate, p-toluenesulfonate and methanesulfonate, the chemical name of the compound shown in formula I
- the pharmaceutically acceptable salts are selected from the group consisting of choline salts, sodium salts, potassium salts, calcium salts, arginine salts, lysine salts, glucose Methylamine salt, ethanolamine salt, bisulfate, hydrochloride, tartrate, maleate, citrate, malate, p-toluenesulfonate and methanesulfonate, the chemical name of the compound shown in formula I
- the stoichiometric ratio of the compound represented by the formula (I) to the base molecule or the acid molecule is 1:0.5 to 1:3, preferably 1:0.5, 1:1, 1:2 or 1: 3. Most preferably 1:1 or 1:2.
- the stoichiometric ratio of the compound represented by the formula (I) to sodium ions is 1:1.
- the stoichiometric ratio of the compound represented by the formula (I) to choline is 1:1.
- the stoichiometric ratio of the compound represented by the formula (I) to potassium ions is 1:1.
- the stoichiometric ratio of the compound represented by the formula (I) to hydrogen sulfate is 1:1.
- the present disclosure provides a method for preparing a pharmaceutically acceptable salt of a compound represented by formula (I), comprising: a step of forming a salt of the compound represented by formula (1) with a base or an acid.
- the solvent used in the salt-forming reaction is selected from isopropanol, methyl tert-butyl ether, isopropyl ether, ethanol, ethyl acetate, acetonitrile, dichloromethane, water, acetone, and n-heptane one or more of.
- the method for preparing the aforementioned pharmaceutically acceptable salts further includes the steps of volatilizing the solvent or crystallizing with stirring, filtering, drying and the like.
- the present disclosure provides a pharmaceutical composition prepared from the aforementioned pharmaceutically acceptable salt.
- the present disclosure provides a pharmaceutical composition, comprising the aforementioned pharmaceutically acceptable salt or the pharmaceutically acceptable salt prepared by the aforementioned method, and optionally a pharmaceutically acceptable carrier, diluent or excipient.
- the present disclosure provides a preparation method of a pharmaceutical composition, comprising the aforementioned pharmaceutically acceptable salt, or the pharmaceutically acceptable salt of the compound of formula (I) prepared by the aforementioned method, and a pharmaceutically acceptable carrier, diluent or excipient Forming agent mixing step.
- the disclosure provides a pharmaceutically acceptable salt of the compound represented by the aforementioned formula (I), or a pharmaceutically acceptable salt prepared by the aforementioned method, or the aforementioned composition, or a composition prepared by the aforementioned method in the preparation of HIV clothing Use in capsid protein inhibitors.
- the present disclosure provides a pharmaceutically acceptable salt of the compound represented by the aforementioned formula (I), or a pharmaceutically acceptable salt prepared by the aforementioned method, or the aforementioned composition, or the composition prepared by the aforementioned method is used in the preparation of Use in a medicament for the prevention and/or treatment of viral infectious diseases, preferably HIV infection.
- the disclosure provides an amorphous form of the choline salt of the compound represented by formula (I), and the diffraction angle 2 ⁇ of its X-ray powder diffraction pattern has no obvious characteristic peaks in the range of 2-48°.
- the present disclosure further provides an amorphous method for preparing the compound choline salt shown in formula (I), selected from: method 1, a) compound choline salt shown in formula (I) and isopropanol, choline hydroxide solution Mix, b) add dichloromethane, dissolve and concentrate;
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing an amorphous choline salt described in the present disclosure further includes a filtering, washing or drying step.
- the disclosure provides the crystal form A of the choline salt of the compound represented by formula (I), the X-ray powder diffraction pattern represented by the diffraction angle 2 ⁇ angle, and has characteristics at 5.183, 8.040, 11.116, 16.998, 18.845, 20.322 and 21.726 peak.
- the X-ray powder diffraction pattern of crystal form A of the choline salt of the compound represented by formula (I) represented by the diffraction angle 2 ⁇ is shown in FIG. 2 .
- the present disclosure further provides a method for preparing crystal form A of the compound choline salt represented by formula (I), which is selected from: method 1, a) mixing the amorphous form of the compound choline salt represented by formula (I) with solvent I, wherein Solvent I is selected from one or more of ethyl acetate, n-heptane and isopropyl acetate, b) beating and crystallization;
- Or method 2 a) mixing the amorphous choline salt of the compound represented by formula (I) with dioxane/n-hexane/isopropyl ether mixture or 4-methyl-2-pentanone, b) stirring and crystallizing.
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing crystal form A of choline salt described in the present disclosure further includes steps such as filtering, washing or drying.
- the present disclosure provides the crystal form B of the choline salt of the compound represented by formula (I), the X-ray powder diffraction pattern represented by the diffraction angle 2 ⁇ angle, with features at 8.056, 10.761, 14.170, 14.835, 20.657, 22.751 and 27.938 peak.
- the crystal form B of the choline salt of the compound represented by formula (I) has characteristic peaks at 8.056, 10.761, 12.289, 14.170, 14.835, 20.657, 21.279, 21.944, 22.751 and 27.938.
- the crystal form B of the choline salt of the compound represented by formula (I) is characterized at 8.056, 10.761, 12.289, 14.170, 14.835, 17.676, 20.657, 21.279, 21.944, 22.751, 25.061, 27.938 and 29.791 peak.
- the X-ray powder diffraction pattern of crystal form B of the choline salt of the compound represented by formula (I) represented by the diffraction angle 2 ⁇ is shown in FIG. 3 .
- the present disclosure further provides a method for preparing the crystal form B of the compound choline salt represented by formula (I), selected from:
- Method 1 a) mixing the compound shown in formula I with choline hydroxide and solvent II, wherein solvent II is selected from at least one of ethanol and isopropanol, b) beating and crystallizing
- the amorphous compound choline salt shown in formula I is mixed with solvent III, wherein solvent III is selected from one of methanol, isopropyl ether, acetonitrile, isopropanol, ethanol, methylene chloride, water and n-hexane or more, b) beating and crystallization;
- Or method 4 a) mixing the crystal form A of the choline salt of the compound represented by formula I with at least one of isopropanol, dichloromethane and n-hexane, and b) beating and crystallizing.
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing crystal form B of choline salt described in the present disclosure further includes steps such as filtering, washing or drying.
- the present disclosure provides an amorphous form of the sodium salt of the compound represented by formula (I), and the diffraction angle 2 ⁇ of its X-ray powder diffraction pattern has no obvious characteristic peaks in the range of 2-48°.
- the disclosure further provides an amorphous method for preparing the sodium salt of the compound represented by formula (I), comprising the steps of: a) compound represented by formula (I) and at least one selected from ethyl acetate, acetonitrile and dichloromethane Solvent and sodium hydroxide solution are mixed, b) n-heptane is added, and solids are precipitated.
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing the amorphous sodium salt described in the present disclosure further includes a step of filtering, washing or drying.
- the disclosure provides the I crystal form of the sodium salt of the compound represented by formula (I), the X-ray powder diffraction pattern represented by the diffraction angle 2 ⁇ angle, and there are characteristic peaks at 5.167, 5.869, 10.671, 17.850, 19.388, 22.646 and 27.604 . In certain embodiments, there are characteristic peaks at 5.167, 5.869, 10.671, 16.031, 17.850, 18.677, 19.388, 22.646, 24.974 and 27.604 in Form I of the sodium salt of the compound represented by formula (I). In some embodiments, the I crystal form of the sodium salt of the compound represented by formula (I) has Characteristic peaks. In certain embodiments, the X-ray powder diffraction pattern of the crystal form I of the sodium salt of the compound represented by formula (I) represented by the diffraction angle 2 ⁇ is shown in FIG. 4 .
- the disclosure further provides a method for the I crystal form of the sodium salt of the compound represented by formula (I), which is selected from: a) mixing the compound represented by formula I with methyl tert-butyl ether and sodium hydroxide solution, heating, and b) stirring Crystallization.
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing the sodium salt I crystal form described in the present disclosure further includes steps such as filtering, washing or drying.
- the present disclosure provides the II crystal form of the sodium salt of the compound represented by formula (I), the X-ray powder diffraction pattern represented by the diffraction angle 2 ⁇ angle, with characteristic peaks at 5.293, 6.788, 10.864, 17.477, 18.966, 20.950 and 23.653 .
- the crystal form II of the sodium salt of the compound represented by formula (I) has characteristic peaks at 5.293, 6.788, 10.864, 16.027, 17.477, 18.966, 20.950, 22.115, 23.653 and 27.156.
- the crystal form II of the sodium salt of the compound represented by formula (I) is at 5.293, 5.561, 6.788, 10.864, 11.332, 13.181, 16.027, 17.477, 18.966, 20.950, 22.115, 23.653, 24.509, 25.979 and 27.156 There are characteristic peaks.
- the X-ray powder diffraction pattern of the crystal form II of the sodium salt of the compound represented by formula (I) represented by the diffraction angle 2 ⁇ is shown in Figure 5 .
- the disclosure further provides a method for preparing the II crystal form of the sodium salt of the compound represented by formula (I), selected from: method 1, a) mixing the compound represented by formula I with methyl tert-butyl ether and sodium hydroxide solution, b ) stirring and crystallizing;
- Or method 3 a) mixing the compound represented by formula I with isopropanol and sodium hydroxide solution, b) adding n-heptane, beating and crystallizing.
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula (I), and can be 1, 5, 10, 15 times in non-limiting embodiments ,20,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140 , 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing the sodium salt II crystal form described in the present disclosure further includes steps such as filtering, washing or drying.
- the disclosure provides the III crystal form of the sodium salt of the compound represented by formula (I), the X-ray powder diffraction pattern represented by the diffraction angle 2 ⁇ angle, and there are characteristic peaks at 6.352, 8.913, 12.297, 18.141, 18.585, 19.373 and 20.718 .
- the crystal form III of the sodium salt of the compound represented by formula (I) has characteristic peaks at 6.352, 8.913, 12.297, 18.141, 18.585, 19.373, 20.718, 21.216, 21.938 and 26.014.
- the III crystal form of the sodium salt of the compound represented by formula (I) has characteristic peaks at 6.352, 8.913, 12.297, 14.919, 16.346, 18.141, 18.585, 19.373, 20.718, 21.216, 21.938, 26.014 and 27.864 .
- the X-ray powder diffraction pattern of the crystal form III of the sodium salt of the compound represented by formula (I) represented by the diffraction angle 2 ⁇ is shown in FIG. 6 .
- the present disclosure further provides a method for the III crystal form of the sodium salt of the compound represented by formula (I), comprising the steps of: a) mixing the compound represented by formula I with isopropanol and sodium hydroxide solution; b) stirring and crystallizing.
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing the sodium salt III crystal form described in the present disclosure further includes steps such as filtering, washing or drying.
- the disclosure provides the IV crystal form of the sodium salt of the compound represented by formula (I), the X-ray powder diffraction pattern represented by the diffraction angle 2 ⁇ angle, and there are characteristic peaks at 6.179, 8.242, 12.509, 13.986, 18.625, 19.522 and 21.746 .
- the IV crystal form of the sodium salt of the compound represented by formula (I) has characteristic peaks at 6.179, 8.242, 8.914, 12.509, 13.986, 18.625, 19.522, 21.454, 21.746 and 22.280.
- the IV crystal form of the sodium salt of the compound represented by formula (I) has characteristic peaks at 6.179, 8.242, 8.914, 12.509, 13.986, 16.762, 18.625, 19.522, 21.454, 21.746, 22.280 and 23.836.
- the X-ray powder diffraction pattern of the sodium salt of the compound represented by formula (I) in the form IV of the sodium salt represented by the diffraction angle 2 ⁇ is shown in FIG. 7 .
- the present disclosure further provides a method for the IV crystal form of the sodium salt of the compound represented by formula (I), comprising the steps of: a) mixing the compound represented by formula I with ethanol and sodium hydroxide solution, heating, and b) stirring and crystallizing.
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing the sodium salt IV crystalline form described in the present disclosure further includes steps such as filtering, washing or drying.
- the disclosure provides the V crystal form of the sodium salt of the compound represented by formula (I), the X-ray powder diffraction pattern represented by the diffraction angle 2 ⁇ angle, and there are characteristic peaks at 4.506, 5.957, 7.986, 13.490, 18.147, 19.213 and 21.300 .
- the crystal form V of the sodium salt of the compound represented by formula (I) has characteristic peaks at 4.506, 5.957, 7.986, 12.219, 13.490, 16.883, 18.147, 19.213, 21.300 and 26.323.
- the V crystal form of the sodium salt of the compound represented by formula (I) has characteristic peaks at 4.506, 5.957, 7.986, 11.172, 12.219, 13.490, 16.883, 18.147, 19.213, 21.300, 23.434, 24.636 and 26.323 .
- the X-ray powder diffraction pattern of the crystal form V of the sodium salt of the compound represented by formula (I) represented by the diffraction angle 2 ⁇ is shown in FIG. 8 .
- the present disclosure further provides a method for the V crystal form of the sodium salt of the compound represented by formula (I), comprising: method 1, a) mixing the compound represented by formula (I) with isopropanol and sodium hydroxide solution, b) stirring and analyzing crystal;
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing the sodium salt Form V described in the present disclosure further includes steps such as filtering, washing or drying.
- the present disclosure provides an amorphous form of the potassium salt of the compound represented by formula (I), and the diffraction angle 2 ⁇ of its X-ray powder diffraction pattern has no obvious characteristic peaks in the range of 2-48°.
- the present disclosure further provides an amorphous method for preparing the potassium salt of the compound represented by formula (I), comprising the steps of: a) mixing the compound represented by formula (I) with acetone and potassium hydroxide solution; b) volatilizing and separating out solids.
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing an amorphous potassium salt described in the present disclosure further includes a step of filtering, washing or drying.
- the present disclosure provides the a crystal form of the potassium salt of the compound represented by formula (I), the X-ray powder diffraction pattern represented by the diffraction angle 2 ⁇ , and there are characteristic peaks at 5.746, 8.304, 12.253 and 20.503.
- the X-ray powder diffraction pattern of crystal form a of the potassium salt of the compound represented by formula (I) represented by the diffraction angle 2 ⁇ is shown in FIG. 9 .
- the disclosure further provides a method for crystal form a of the potassium salt of the compound represented by formula (I), comprising the steps of: a) mixing the compound represented by formula (I) with methyl tert-butyl ether and potassium hydroxide solution, b) stirring Crystallization.
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing crystal form a of the potassium salt described in the present disclosure further includes steps such as filtering, washing or drying.
- the disclosure provides an amorphous form of bisulfate of the compound represented by formula (I), and the diffraction angle 2 ⁇ of its X-ray powder diffraction pattern has no obvious characteristic peaks in the range of 2-48°.
- the present disclosure further provides an amorphous method for preparing bisulfate of the compound represented by formula (I), comprising the steps of: a) mixing the compound represented by formula (I) with ethyl acetate and sulfuric acid aqueous solution, and b) volatilization and crystallization.
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing amorphous bisulfate salt described in the present disclosure further includes a filtering, washing or drying step.
- the present disclosure provides the A crystal form of the hydrogen sulfate salt of the compound represented by the formula (I), the X-ray powder diffraction pattern represented by the diffraction angle 2 ⁇ angle, and has characteristics at 7.101, 13.538, 15.870, 18.959, 20.570, 23.649 and 24.320 peak.
- the crystal form A of the hydrogen sulfate salt of the compound represented by formula (I) has characteristic peaks at 7.101, 12.742, 13.538, 15.870, 18.959, 20.570, 21.603, 22.055, 23.649 and 24.320.
- the crystal form A of the hydrogen sulfate salt of the compound represented by formula (I) is characterized at 7.101, 10.933, 12.742, 13.538, 14.966, 15.870, 18.959, 20.570, 21.603, 22.055, 23.649, 24.320 and 26.799 peak.
- the X-ray powder diffraction pattern of crystal form A of the bisulfate salt of the compound represented by formula (I) represented by the diffraction angle 2 ⁇ is shown in FIG. 10 .
- the present disclosure further provides a method for compound bisulfate A crystal form shown in formula (I), comprising: a) mixing compound shown in formula I with methyl tert-butyl ether, sulfuric acid solution or ethanol/water solution; b) stirring and analyzing crystal.
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing crystal form A of bisulfate salt described in the present disclosure further includes steps such as filtering, washing or drying.
- the present disclosure provides an amorphous form of the calcium salt of the compound represented by formula (I), and the diffraction angle 2 ⁇ of its X-ray powder diffraction pattern has no obvious characteristic peaks in the range of 2-48°.
- the present disclosure further provides an amorphous method for preparing the calcium salt of the compound represented by formula (I), comprising the steps of: a) mixing the compound represented by formula (I) with acetone and calcium hydroxide solution; b) volatilizing and separating out solids.
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the methods for preparing amorphous calcium salts described in the present disclosure further include filtering, washing or drying steps.
- the present disclosure provides an amorphous form of the arginine salt of the compound represented by formula (I), and the diffraction angle 2 ⁇ of its X-ray powder diffraction pattern has no obvious characteristic peaks in the range of 2-48°.
- the disclosure further provides an amorphous method for preparing the arginine salt of the compound represented by formula (I), comprising the steps of: a) mixing the compound represented by formula (I) with ethanol/water and arginine solution, b) volatilizing, Solid precipitated out.
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing an amorphous arginine salt described in the present disclosure further includes a step of filtering, washing or drying.
- the present disclosure provides the amorphous form of the lysine salt of the compound represented by formula (I), and the diffraction angle 2 ⁇ of its X-ray powder diffraction pattern has no obvious characteristic peaks in the range of 2-48°.
- the present disclosure further provides an amorphous method for preparing the lysine salt of the compound shown in formula (I), comprising the steps of: a) mixing the compound shown in formula (I) with methyl tert-butyl ether and lysine solution, b ) volatilizes, and the solid precipitates out.
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing an amorphous lysine salt described in the present disclosure further includes a step of filtering, washing or drying.
- the disclosure provides an amorphous form of meglumine salt of the compound represented by formula (I), and the diffraction angle 2 ⁇ of its X-ray powder diffraction pattern has no obvious characteristic peaks in the range of 2-48°.
- the disclosure further provides an amorphous method for preparing the compound meglumine salt shown in formula (I), comprising the steps of: a) mixing the compound shown in formula (I) with acetone and meglumine solution, b) volatilization, and solid precipitation .
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing the amorphous meglumine salt described in the present disclosure further includes the steps of filtering, washing or drying.
- the present disclosure provides an amorphous form of ethanolamine salt of the compound represented by formula (I), and the diffraction angle 2 ⁇ of its X-ray powder diffraction pattern has no obvious characteristic peaks in the range of 2-48°.
- the present disclosure further provides an amorphous method for preparing the ethanolamine salt of the compound represented by formula (I), comprising the steps of: a) mixing the compound represented by formula (I) with ethanol/water and ethanolamine solution; b) volatilization, and solid precipitation.
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing the amorphous ethanolamine salt described in the present disclosure further includes a filtering, washing or drying step.
- the present disclosure provides an amorphous form of the hydrochloride salt of the compound represented by formula (I), and the diffraction angle 2 ⁇ of its X-ray powder diffraction pattern has no obvious characteristic peaks in the range of 2-48°.
- the present disclosure further provides an amorphous method for preparing the hydrochloride of the compound represented by formula (I), comprising the steps of: a) mixing the compound represented by formula (I) with ethanol/water and hydrochloric acid solution; b) volatilization, and solid precipitation.
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing the amorphous hydrochloride salt described in the present disclosure further includes a filtering, washing or drying step.
- the present disclosure provides an amorphous form of tartrate salt of the compound represented by formula (I), and the diffraction angle 2 ⁇ of its X-ray powder diffraction pattern has no obvious characteristic peaks in the range of 2-48°.
- the present disclosure further provides an amorphous method for preparing the tartrate salt of the compound represented by formula (I), comprising the steps of: a) mixing the compound represented by formula (I) with ethanol/water and tartaric acid solution; b) volatilization and solid precipitation.
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing amorphous tartrate salt described in the present disclosure further comprises a step of filtering, washing or drying.
- the present disclosure provides an amorphous form of the maleate salt of the compound represented by formula (I), and the diffraction angle 2 ⁇ of its X-ray powder diffraction pattern has no obvious characteristic peaks in the range of 2-48°.
- the disclosure further provides an amorphous method for preparing the maleate of the compound shown in formula (I), comprising the steps of: a) mixing the compound shown in formula (I) with methyl tert-butyl ether and maleic acid solution, b ) volatilizes, and the solid precipitates out.
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing the amorphous maleate salt described in the present disclosure further includes a step of filtering, washing or drying.
- the present disclosure provides an amorphous form of the citrate compound represented by formula (I), and the diffraction angle 2 ⁇ of its X-ray powder diffraction pattern has no obvious characteristic peaks in the range of 2-48°.
- the present disclosure further provides an amorphous method for preparing the compound citrate represented by formula (I), comprising the steps of: a) mixing the compound represented by formula (I) with methyl tert-butyl ether and citric acid solution, and b) volatilizing , solid precipitated out.
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing amorphous citrate described in the present disclosure further includes filtering, washing or drying steps.
- the present disclosure provides an amorphous form of malate salt of the compound represented by formula (I), and the diffraction angle 2 ⁇ of its X-ray powder diffraction pattern has no obvious characteristic peaks in the range of 2-48°.
- the disclosure further provides an amorphous method for preparing malate of the compound shown in formula (I), comprising the steps of: a) mixing the compound shown in formula (I) with methyl tert-butyl ether and malic acid solution, b) volatilizing , solid precipitated out.
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing amorphous malate described in the present disclosure further includes a filtering, washing or drying step.
- the present disclosure provides an amorphous form of p-toluenesulfonate of the compound represented by formula (I), and the diffraction angle 2 ⁇ of its X-ray powder diffraction pattern has no obvious characteristic peaks in the range of 2-48°.
- the disclosure further provides an amorphous method for preparing the p-toluenesulfonic acid salt of the compound represented by the formula (I), comprising the steps of: a) mixing the compound represented by the formula (I) with methyl tert-butyl ether and p-toluenesulfonic acid solution , b) volatilization, solid precipitation.
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing the amorphous p-toluenesulfonate salt described in the present disclosure further includes a filtering, washing or drying step.
- the present disclosure provides an amorphous form of the mesylate salt of the compound represented by formula (I), and the diffraction angle 2 ⁇ of its X-ray powder diffraction pattern has no obvious characteristic peaks in the range of 2-48°.
- the present disclosure further provides an amorphous method for preparing the compound mesylate shown in formula (I), comprising the steps of: a) mixing the compound shown in formula (I) with methyl tert-butyl ether and methanesulfonic acid solution, b ) volatilizes, and the solid precipitates out.
- the volume ( ⁇ l) of the solvent used in the present disclosure can be 1-200 times the mass (mg) of the compound of formula I, and can be 1, 5, 10, 15, 20 times in non-limiting embodiments. ,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95,100,105,110,115,120,125,130,135,140,145 , 150, 155, 160, 165, 170, 175, 180, 185, 190, 200.
- the method for preparing the amorphous mesylate salt described in the present disclosure further includes a filtering, washing or drying step.
- the present disclosure also provides a pharmaceutical composition prepared from the crystal form of the pharmaceutically acceptable salt of the compound represented by the aforementioned formula (I).
- the present disclosure also provides a pharmaceutical composition, comprising the aforementioned crystal form of the pharmaceutically acceptable salt and optionally a pharmaceutically acceptable carrier, diluent or excipient.
- the present disclosure also provides a preparation method of a pharmaceutical composition, which includes the step of mixing the aforementioned pharmaceutically acceptable salt crystal form with a pharmaceutically acceptable carrier, diluent or excipient.
- the present disclosure also provides the use of the aforementioned pharmaceutically acceptable salt crystal form, or the aforementioned composition, or the composition prepared by the aforementioned method in the preparation of an HIV capsid protein inhibitor.
- the present disclosure also provides the use of the crystalline form of the aforementioned pharmaceutically acceptable salt, or the aforementioned composition, or the composition prepared by the aforementioned method in the preparation of medicines for preventing and/or treating viral infectious diseases, preferably HIV infection .
- the "2 ⁇ or 2 ⁇ angle" described in the present disclosure refers to the diffraction angle, ⁇ is the Bragg angle, and the unit is ° or degree; the error range of each characteristic peak 2 ⁇ is ⁇ 0.20 (including numbers exceeding 1 decimal place after rounding) case), can be -0.20, -0.19, -0.18, -0.17, -0.16, -0.15, -0.14, -0.13, -0.12, -0.11, -0.10, -0.09, -0.08, -0.07, -0.06, -0.05, -0.04, -0.03, -0.02, -0.01, 0.00, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17 , 0.18, 0.19, 0.20.
- Deliquescence absorption of sufficient water to form a liquid
- the weight gain of moisture is not less than 15%;
- Moisture-absorbing the weight gain of moisture-absorbing is less than 15% but not less than 2%;
- Differential scanning calorimetry or DSC in this disclosure refers to measuring the temperature difference and heat flow difference between the sample and the reference object during the sample heating or constant temperature process, so as to characterize all the physical changes related to thermal effects and Chemical changes, to obtain the phase transition information of the sample.
- the drying temperature described in the present disclosure is generally 25° C. to 150° C., preferably 40° C. to 80° C., and can be dried under normal pressure or reduced pressure.
- “Pharmaceutical composition” means a mixture containing one or more compounds of formula (I) described herein or a pharmaceutically acceptable salt thereof and other chemical components, as well as other components such as pharmaceutically acceptable carriers and excipients.
- the purpose of the pharmaceutical composition is to promote the administration to the organism, facilitate the absorption of the active ingredient and thus exert biological activity.
- the crystal forms described in the present disclosure include but are not limited to solvates of compounds represented by formula (I), and the solvents include but are not limited to ethyl acetate/n-heptane, isopropyl acetate/n-heptane, methanol/ Isopropyl ether, acetonitrile/isopropyl ether, dichloromethane/isopropyl ether, ethanol/water, water/isopropanol, ethanol/n-hexane, ethanol, isopropanol, methylene chloride/n-hexane, dioxane /n-hexane/isopropyl ether, 4-methyl-2-pentanone, methyl tert-butyl ether, ethanol, ethyl acetate, acetonitrile, dichloromethane, ethanol/isopropanol, ethanol/n-heptane.
- the solvents include but are not limited
- solvate in the present disclosure includes, but is not limited to, a complex formed by combining the compound of formula (I) with a solvent.
- Figure 1 XRPD spectrum of the amorphous choline salt of the compound represented by formula (I).
- Figure 2 XRPD pattern of the crystal form A of the compound choline salt represented by formula (I).
- Figure 3 XRPD spectrum of the crystal form B of the compound choline salt represented by formula (I).
- Fig. 6 XRPD spectrum of the sodium salt III crystal form of the compound represented by formula (I).
- Figure 8 XRPD pattern of the sodium salt V crystal form of the compound represented by formula (I).
- Fig. 9 XRPD pattern of the crystal form a of the potassium salt of the compound represented by formula (I).
- NMR nuclear magnetic resonance
- MS mass spectroscopy
- MS was determined with Agilent 1200/1290 DAD-6110/6120 Quadrupole MS liquid mass spectrometer (manufacturer: Agilent, MS model: 6110/6120 Quadrupole MS), waters ACQuity UPLC-QD/SQD (manufacturer: waters, MS Model: waters ACQuity Qda Detector/waters SQ Detector), THERMO Ultimate 3000-Q Exactive (manufacturer: THERMO, MS model: THERMO Q Exactive).
- HPLC High performance liquid chromatography
- Chiral HPLC analysis was performed using an Agilent 1260 DAD high performance liquid chromatograph.
- the CombiFlash rapid preparation instrument uses Combiflash Rf200 (TELEDYNE ISCO).
- the thin-layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate.
- the specification of the silica gel plate used in thin-layer chromatography (TLC) is 0.15 mm to 0.2 mm, and the specification of thin-layer chromatography separation and purification products is 0.4 mm. ⁇ 0.5mm.
- Silica gel column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.
- the known starting materials of the present disclosure can be adopted or synthesized according to methods known in the art, or can be purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Shaoyuan Chemical Technology (Accela ChemBio Inc), Darui chemical companies.
- the reactions can all be carried out under an argon atmosphere or a nitrogen atmosphere.
- the argon atmosphere or nitrogen atmosphere means that the reaction bottle is connected to an argon or nitrogen balloon with a volume of about 1 L.
- the hydrogen atmosphere means that the reaction bottle is connected to a hydrogen balloon with a capacity of about 1L.
- the pressurized hydrogenation reaction uses Parr 3916EKX hydrogenation instrument and Qinglan QL-500 hydrogen generator or HC2-SS hydrogenation instrument.
- the hydrogenation reaction is usually vacuumized and filled with hydrogen, and the operation is repeated 3 times.
- the solution refers to an aqueous solution.
- reaction temperature is room temperature, which is 20°C to 30°C.
- the monitoring of the reaction process in the embodiment adopts thin-layer chromatography (TLC), the developer used for reaction, the eluent system of the column chromatography that purifies compound adopts and the developer system of thin-layer chromatography comprise: A: n-hexane/ethyl acetate system, B: dichloromethane/methanol system, the volume ratio of the solvent is adjusted according to the polarity of the compound, and can also be adjusted by adding a small amount of basic or acidic reagents such as triethylamine and acetic acid.
- TLC thin-layer chromatography
- DVS dynamic moisture adsorption
- the test uses SMS DVS Advantage, at 25°C, the humidity is from 0-95%, the step is 10%, the judgment standard is that the quality change dM/dT of each gradient is less than 0.002%, TMAX 360min, and the cycle is two cycles.
- Embodiment 1 the preparation of compound shown in formula (I)
- 1,4-Dibromo-6,7-dihydro-5H-cyclopenta[c]pyridine-3-carboxylic acid ethyl ester 1a (7.2g, 20.6mmol, using the literature "Advanced Synthesis & Catalysis.2016,358,1916 -1923" prepared by known method) was dissolved in anhydrous tetrahydrofuran (50mL), cooled to 0°C, and lithium borohydride (450mg, 20.6mmol, Shanghai Sinopharm Chemical Reagent Co., Ltd.) was added. Stir at room temperature for 18 hours.
- Triethylamine (1.25 g, 12.4 mmol, Shanghai Sinopharm Group Chemical Reagent Co., Ltd.) was added, stirred at -78°C for 30 minutes, and then stirred at 0°C for 1.5 hours.
- Test example 1 the impact of formula (I) compound on HIV-1 capsid protein polymerization in vitro
- His-CA 3.His-tagged HIV-1 capsid protein
- GST-CA GST-tagged HIV-1 capsid protein
- HIV-1 capsid protein aggregates spontaneously in high salt solution.
- the capsid protein derived from HIV-1 NL4-3 strain was tagged and expressed with 6His tag and GST tag respectively, and purified.
- mix His-CA and GST-CA use Eu3+-Cryptate (energy donor)-labeled GST antibody and XL665 (energy acceptor)-labeled His antibody to detect capsid protein polymerization Level.
- the energy donor and the energy acceptor can be pulled close enough, and the energy donor is outside Under the excitation of the light source (such as xenon lamp or laser), the captured energy is partially released, and the emission wavelength is 620nM, and part of the resonance is transferred to the energy acceptor to excite it, and the emission wavelength is 665nM to generate a light signal, and its signal intensity is multimerized with the tagged protein The degree is proportional.
- the compound was first prepared with DMSO to 20mM, and then diluted with DMSO to the first concentration of 2mM, and then diluted to 8 concentrations by 5 times in sequence, and DMSO was added to the control wells, and the serially diluted compound was then diluted 20 times with protein diluent to 10 double the working concentration.
- the compound of formula (I) inhibits the multimerization of HIV-1 capsid protein, and the measured EC50 value is shown in the table below:
- Embodiment 2 Preparation of amorphous choline salt
- the nuclear magnetic (HNMR) detection result of the obtained product the molar ratio of the compound of formula (I) and choline in the salt is about 1:1.
- Embodiment 3 the preparation of choline salt amorphous
- Embodiment 4 Preparation of choline salt crystal form A
- the product was defined as crystal form A, the XRPD spectrum is shown in Figure 2, and the positions of its characteristic peaks are shown in Table 1.
- Embodiment 5 Preparation of choline salt crystal form A
- the choline salt amorphous (60mg) of the compound represented by formula (I) was added to 0.5mL 4-methyl-2-pentanone, dissolved, stirred at room temperature to precipitate a solid, and the solid was vacuum-dried to obtain the product. Detected by X-ray powder diffractometer, the product is crystal form A.
- Embodiment 6 Preparation of choline salt crystal form B
- the compound represented by formula (I) (740 mg) and choline hydroxide (198 mg, 47% aqueous solution) were added to isopropanol, stirred at room temperature, filtered, and the filter cake was vacuum-dried to obtain the product. After detection by X-ray powder diffractometer, the product was defined as crystal form B.
- the XRPD spectrum is shown in Figure 3, and the positions of its characteristic peaks are shown in Table 2.
- the DSC spectrum shows that the peak endothermic peaks are 65.75°C and 178.03°C.
- the TGA spectrum shows that the weight loss is 1.06% at 25°C-150°C.
- Embodiment 7 Preparation of choline salt crystal form B
- Embodiment 8 Preparation of choline salt crystal form B
- Embodiment 9 Preparation of choline salt crystal form B
- Embodiment 10 Preparation of choline salt crystal form B
- Embodiment 11 Preparation of choline salt crystal form B
- Embodiment 12 Preparation of choline salt B crystal form
- Embodiment 13 Preparation of choline salt B crystal form
- Embodiment 15 Preparation of sodium salt crystal form I
- Embodiment 18 Preparation of sodium salt II crystal form
- the crystal form I of the sodium salt of the compound represented by formula (I) was heated to 160° C., kept at a constant temperature for 1 minute, and then cooled to room temperature to obtain a solid product. Detected by X-ray powder diffractometer, the product is crystal form II.
- Embodiment 19 Preparation of sodium salt II crystal form
- Embodiment 20 Preparation of sodium salt III crystal form
- the compound bisulfate crystal form A, sodium salt crystal form II, sodium salt crystal form III, potassium salt crystal form a and choline salt crystal form B of the compound shown in formula (I) were placed on a flat surface respectively, and respectively investigated at high temperature (40°C, 60°C), high humidity (RH 75%, RH 92.5%), the stability of the sample is 30 days, and the experimental results are shown in Table 11-15:
- the compound represented by formula I is placed in crystalline form A of bisulfate salt, crystalline form II of sodium salt, crystalline form III of sodium salt, crystalline form A of potassium salt and crystalline form B of choline salt respectively at 4°C, 25°C, 60% RH and 40°C, 75% RH conditions to examine its stability, the experimental results are shown in Table 16-20.
Abstract
本公开涉及一种稠合吡啶环衍生物的可药用盐、晶型及其制备方法。具体而言,本公开涉及如式(I)所示化合物的胆碱盐、钠盐、钾盐、钙盐、精氨酸盐、赖氨酸盐、葡甲胺盐、乙醇胺盐、硫酸氢盐、盐酸盐、酒石酸盐、马来酸盐、柠檬酸盐、苹果酸盐、对甲苯磺酸盐和甲磺酸盐,以及结晶形式。
Description
本申请要求申请日为2021年5月28日的中国专利申请2021105894636的优先权。本申请引用上述中国专利申请的全文。
本公开涉及一种稠合吡啶环衍生物的可药用盐、晶型及其制备方法,具体的,提供了如式I所示化合物的胆碱盐、钠盐、钾盐、钙盐、精氨酸盐、赖氨酸盐、葡甲胺盐、乙醇胺盐、硫酸氢盐、盐酸盐、酒石酸盐、马来酸盐、柠檬酸盐、苹果酸盐、对甲苯磺酸盐和甲磺酸盐,以及结晶形式。
艾滋病又称获得性免疫缺陷综合症(acquire immunodeficiency syndrome,AIDS),是由人类免疫缺陷病毒(HIV)引起的一种致死性传染病,其发病机制主要是在HIV病毒直接和间接作用下,促使CD4
+T淋巴细胞功能受损和大量破坏,导致细胞免疫缺陷,进而引起各种严重的机会性感染和肿瘤的发生。如今,全球范围超过3500万人已感染了HIV病毒。
目前针对HIV感染者的疗法由高活性抗逆转录病毒药物(HAART)组合而成,主要包括核苷酸逆转录抑制剂(NRTIs),非核苷酸逆转录酶抑制剂(NNRTIs),蛋白酶抑制剂(PIs),整合酶链转移抑制剂(INIs)或进入抑制剂。这些药物通过靶向HIV病毒复制周期中各个阶段的病毒酶或病毒蛋白,有效的抑制病毒载量和传送速率,显著延缓了病情的进展,从而延长了病人的生命(Engelman,A.,Cherepanov,P.,Nature Reviews 2012,10,279-290;Flexner,C.,Nature Rev.Drug Discov.2007,6,959-966)。
但是由于1型人类免疫缺陷病毒(HIV-1)的快速复制和高突变率,使得这些组合疗法容易产生有耐药性的HIV病毒株,最终导致药物失效,病毒逃逸,病情恶化(Grant,R.M.,Hecht,F.M.,Warmerdam,M.,JAMA 2002,288,181-188-559;Smith,R.J.,Okano,J.T.,Kahn,J.S.,Bodine,E.N.,Blower,S.,Science 2010,327,697-701)。因此,迫切需要研发针对新出现的抗药性HIV变体具有活性的新型抗逆转录病毒药物。特别是研发的新药要对耐药性产生高度遗传障碍,并且相对于现有药物具有更高的安全性和病人依从性。
WO2021104413提供了一种如式I所示的化合物,其化学名为N-((S)-1-((R)-4-(4-氯-3-(甲磺酰胺)-1-(2,2,2-三氟乙基)-1H-吲唑-7-基)-1-(3-甲基-3-(甲磺酰基)丁-1-炔-1-基)-6,7- 二氢-5H-环戊并[c]吡啶-3-基)-2-(3,5-二氟苯基)乙基)-2-((3bS,4aR)-5,5-二氟-3-(三氟甲基)-3b,4,4a,5-四氢-1H-环丙并[3,4]环戊并[1,2-c]吡唑-1-基)乙酰胺,该化合物具有较好的HIV-1衣壳蛋白抑制作用,
发明内容
本公开提供如式(I)所示化合物的可药用盐,其中所述可药用盐选自胆碱盐、钠盐、钾盐、钙盐、精氨酸盐、赖氨酸盐、葡甲胺盐、乙醇胺盐、硫酸氢盐、盐酸盐、酒石酸盐、马来酸盐、柠檬酸盐、苹果酸盐、对甲苯磺酸盐和甲磺酸盐,式I所示化合物的化学名为N-((S)-1-((R)-4-(4-氯-3-(甲磺酰胺)-1-(2,2,2-三氟乙基)-1H-吲唑-7-基)-1-(3-甲基-3-(甲磺酰基)丁-1-炔-1-基)-6,7-二氢-5H-环戊并[c]吡啶-3-基)-2-(3,5-二氟苯基)乙基)-2-((3bS,4aR)-5,5-二氟-3-(三氟甲基)-3b,4,4a,5-四氢-1H-环丙并[3,4]环戊并[1,2-c]吡唑-1-基)乙酰胺,
在某些实施方案中,所述式(I)所示化合物与碱分子或酸分子的化学配比为1:0.5~1:3,优选1:0.5、1:1、1:2或1:3,最优选1:1或1:2。在某些实施方案中,所述式(I)所示化合物与钠离子的化学配比为1:1。在某些实施方案中,所述式(I)所示化合物与胆碱的化学配比为1:1。在某些实施方案中,所述式(I)所示化合物与钾离子的化学配比为1:1。在某些实施方案中,所述式(I)所示化合物与硫酸氢根的化学配比为1:1。
本公开提供了制备式(I)所示化合物可药用盐的方法,包括:式(1)所述化合物与碱或酸成盐的步骤。在某些实施方案中,所述成盐反应所用的溶剂选自异丙醇、甲基叔丁基醚、异丙醚、乙醇、乙酸乙酯、乙腈、二氯甲烷、水、丙酮和正庚烷中的一种或多种。
在某些实施方案中,制备前述可药用盐的方法还包括挥发溶剂或搅拌析晶,过滤、 干燥等步骤。
本公开提供了一种由前述的可药用盐制备得到的药物组合物。
本公开提供了一种药物组合物,含有前述可药用盐或由前述方法制备得到的可药用盐,和任选自药学上可接受的载体、稀释剂或赋形剂。
本公开提供一种药物组合物的制备方法,包括将前述可药用盐,或由前述方法制备得到的式(I)化合物的可药用盐,与药学上可接受的载体、稀释剂或赋形剂混合的步骤。
本公开提供了一种前述式(I)所示化合物的可药用盐,或由前述方法制备得到的可药用盐,或前述组合物,或由前述方法制备得到的组合物在制备HIV衣壳蛋白抑制剂中的用途。
本公开提供了一种前述式(I)所示化合物的可药用盐,或由前述方法制备得到的可药用盐,或前述组合物,或由前述方法制备得到的组合物在制备用于预防和/或治疗病毒性感染疾病的药物中的用途,优选HIV感染。
本公开提供了式(I)所示化合物胆碱盐的无定形,其X-射线粉末衍射图谱的衍射角2θ在2-48°范围内没有明显特征峰。
本公开进一步提供了制备式(I)所示化合物胆碱盐的无定形的方法,选自:方法1,a)式(I)所示化合物胆碱盐与异丙醇,氢氧化胆碱溶液混合,b)加入二氯甲烷,溶清,浓缩;
或者方法2,a)式(I)所示化合物与甲基叔丁基醚,氢氧化胆碱溶液混合,b)加入正庚烷,固体析出。
在某些实施方式中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方式中,本公开所述的制备胆碱盐无定形方法还包括过滤、洗涤或干燥步骤。
本公开提供了式(I)所示化合物胆碱盐的A晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在5.183、8.040、11.116、16.998、18.845、20.322和21.726处有特征峰。在某些实施方案中,式(I)所示化合物胆碱盐的A晶型以衍射角2θ角度表示的X-射线粉末衍射图谱如图2所示。
本公开进一步提供了制备式(I)所示化合物胆碱盐的A晶型的方法,选自:方法1,a)式(I)所示化合物胆碱盐的无定形与溶剂I混合,其中溶剂I选自乙酸乙酯、正庚烷和乙酸异丙酯中的一种或多种,b)打浆析晶;
或者方法2,a)式(I)所示化合物胆碱盐的无定形与二氧六环/正己烷/异丙醚混合物或4-甲基-2-戊酮混合,b)搅拌析晶。
在某些实施方案中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方案中,本公开所述的制备胆碱盐A晶型方法还包括过滤、洗涤或干燥等步骤。
本公开提供了式(I)所示化合物胆碱盐的B晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在8.056、10.761、14.170、14.835、20.657、22.751和27.938处有特征峰。在某些实施方案中,式(I)所示化合物胆碱盐的B晶型在8.056、10.761、12.289、14.170、14.835、20.657、21.279、21.944、22.751和27.938处有特征峰。在某些实施方案中,式(I)所示化合物胆碱盐的B晶型在8.056、10.761、12.289、14.170、14.835、17.676、20.657、21.279、21.944、22.751、25.061、27.938和29.791处有特征峰。在某些实施方案中,式(I)所示化合物胆碱盐的B晶型以衍射角2θ角度表示的X-射线粉末衍射图谱如图3所示。
本公开进一步提供了制备式(I)所示化合物胆碱盐的B晶型的方法,选自:
方法1,a)式I所示化合物与氢氧化胆碱、溶剂II混合,其中溶剂II选自乙醇和异丙醇中的至少一种,b)打浆析晶
或者方法2,a)式I所示化合物与氢氧化胆碱、乙醇混合,b)加入异丙醇或正庚烷析晶;
或者方法3,式I所示化合物胆碱盐无定形与溶剂III混合,其中溶剂III选自甲醇、异丙醚、乙腈、异丙醇、乙醇、二氯甲烷、水和正己烷中的一种或多种,b)打浆析晶;
或者方法4,a)式I所示化合物胆碱盐的A晶型与异丙醇、二氯甲烷和正己烷中的至少一种混合,b)打浆析晶。
在某些实施方案中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方案中,本公开所述的制备胆碱盐B晶型方法还包括过滤、洗涤或干燥等步骤。
本公开提供了式(I)所示化合物钠盐的无定形,其X-射线粉末衍射图谱的衍射角2θ在2-48°范围内没有明显特征峰。
本公开进一步提供了制备式(I)所示化合物钠盐的无定形的方法,包括步骤:a)式(I)所示化合物与选自乙酸乙酯、乙腈和二氯甲烷中的至少一种溶剂,氢氧化钠溶液混合,b)加入正庚烷,固体析出。
在某些实施方式中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方式中,本公开所述的制备钠盐无定形方法还包括过滤、洗涤或干燥步骤。
本公开提供了式(I)所示化合物钠盐的I晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在5.167、5.869、10.671、17.850、19.388、22.646和27.604处有特征峰。在某些实施方案中,式(I)所示化合物钠盐的I晶型5.167、5.869、10.671、16.031、17.850、18.677、19.388、22.646、24.974和27.604处有特征峰。在某些实施方案中,式(I)所示化合物钠盐的I晶型在5.167、5.869、9.409、10.671、12.035、16.031、17.850、18.677、19.388、21.811、22.646、23.483、24.974和27.604处有特征峰。在某些实施方案中,式(I)所示化合物钠盐的I晶型以衍射角2θ角度表示的X-射线粉末衍射图谱如图4所示。
本公开进一步提供了式(I)所示化合物钠盐的I晶型的方法,选自:a)式I所示化合物与甲基叔丁基醚、氢氧化钠溶液混合,加热,b)搅拌析晶。
在某些实施方案中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方案中,本公开所述的制备钠盐I晶型方法还包括过滤、洗涤或干燥等步骤。
本公开提供了式(I)所示化合物钠盐的II晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在5.293、6.788、10.864、17.477、18.966、20.950和23.653处有特征峰。在某些实施方案中,式(I)所示化合物钠盐的II晶型在5.293、6.788、10.864、16.027、17.477、18.966、20.950、22.115、23.653和27.156处有特征峰。在某些实施方案中,式(I)所示化合物钠盐的II晶型在5.293、5.561、6.788、10.864、11.332、13.181、16.027、17.477、18.966、20.950、22.115、23.653、24.509、25.979和27.156处有特征峰。在某些实施方案中,式(I)所示化合物钠盐的II晶型以衍射角2θ角度表示的X-射线粉末衍射图谱如图5所示。
本公开进一步提供了制备式(I)所示化合物钠盐的II晶型的方法,选自:方法1, a)式I所示化合物与甲基叔丁基醚、氢氧化钠溶液混合,b)搅拌析晶;
或者方法2,a)式I所示化合物钠盐的I晶型,加热至160℃;
或者方法3,a)式I所示化合物与异丙醇、氢氧化钠溶液混合,b)加入正庚烷,打浆析晶。
在某些实施方案中,本公开所述溶剂所用体积(μl)可以为式(I)化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方案中,本公开所述的制备钠盐II晶型方法还包括过滤、洗涤或干燥等步骤。
本公开提供了式(I)所示化合物钠盐的III晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在6.352、8.913、12.297、18.141、18.585、19.373和20.718处有特征峰。在某些实施方案中,式(I)所示化合物钠盐的III晶型在6.352、8.913、12.297、18.141、18.585、19.373、20.718、21.216、21.938和26.014处有特征峰。在某些实施方案中,式(I)所示化合物钠盐的III晶型在6.352、8.913、12.297、14.919、16.346、18.141、18.585、19.373、20.718、21.216、21.938、26.014和27.864处有特征峰。在某些实施方案中,式(I)所示化合物钠盐的III晶型以衍射角2θ角度表示的X-射线粉末衍射图谱如图6所示。
本公开进一步提供了式(I)所示化合物钠盐的III晶型的方法,包括步骤:a)式I所示化合物与异丙醇、氢氧化钠溶液混合,b)搅拌析晶。
在某些实施方案中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方案中,本公开所述的制备钠盐III晶型方法还包括过滤、洗涤或干燥等步骤。
本公开提供了式(I)所示化合物钠盐的IV晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在6.179、8.242、12.509、13.986、18.625、19.522和21.746处有特征峰。在某些实施方案中,式(I)所示化合物钠盐的IV晶型在6.179、8.242、8.914、12.509、13.986、18.625、19.522、21.454、21.746和22.280处有特征峰。在某些实施方案中,式(I)所示化合物钠盐的IV晶型在6.179、8.242、8.914、12.509、13.986、16.762、18.625、19.522、21.454、21.746、22.280和23.836处有特征峰。在某些实施方案中,式(I)所示化合物钠盐的IV晶型以衍射角2θ角度表示的X-射线粉末衍射图谱如图7所示。
本公开进一步提供了式(I)所示化合物钠盐的IV晶型的方法,包括步骤:a)式I所示化合物与乙醇、氢氧化钠溶液混合,加热,b)搅拌析晶。
在某些实施方案中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方案中,本公开所述的制备钠盐IV晶型方法还包括过滤、洗涤或干燥等步骤。
本公开提供了式(I)所示化合物钠盐的V晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在4.506、5.957、7.986、13.490、18.147、19.213和21.300处有特征峰。在某些实施方案中,式(I)所示化合物钠盐的V晶型在4.506、5.957、7.986、12.219、13.490、16.883、18.147、19.213、21.300和26.323处有特征峰。在某些实施方案中,式(I)所示化合物钠盐的V晶型在4.506、5.957、7.986、11.172、12.219、13.490、16.883、18.147、19.213、21.300、23.434、24.636和26.323处有特征峰。在某些实施方案中,式(I)所示化合物钠盐的V晶型以衍射角2θ角度表示的X-射线粉末衍射图谱如图8所示。
本公开进一步提供了式(I)所示化合物钠盐的V晶型的方法,包括:方法1,a)式(I)所示化合物与异丙醇、氢氧化钠溶液混合,b)搅拌析晶;
或者方法2,a)选自式I所示化合物的II晶型、III晶型和IV晶型中的一种或多种,与异丙醚或异丙醇混合,b)打浆析晶。
在某些实施方案中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方案中,本公开所述的制备钠盐V晶型方法还包括过滤、洗涤或干燥等步骤。
本公开提供了式(I)所示化合物钾盐的无定形,其X-射线粉末衍射图谱的衍射角2θ在2-48°范围内没有明显特征峰。
本公开进一步提供了制备式(I)所示化合物钾盐的无定形的方法,包括步骤:a)式(I)所示化合物与丙酮,氢氧化钾溶液混合,b)挥发,固体析出。
在某些实施方式中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方式中,本公 开所述的制备钾盐无定形方法还包括过滤、洗涤或干燥步骤。
本公开提供了式(I)所示化合物钾盐的a晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在5.746、8.304、12.253和20.503处有特征峰。在某些实施方案中,式(I)所示化合物钾盐的a晶型以衍射角2θ角度表示的X-射线粉末衍射图谱如图9所示。
本公开进一步提供了式(I)所示化合物钾盐的a晶型的方法,包括步骤:a)式(I)所示化合物与甲基叔丁基醚、氢氧化钾溶液混合,b)搅拌析晶。
在某些实施方案中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方案中,本公开所述的制备钾盐a晶型方法还包括过滤、洗涤或干燥等步骤。
本公开提供了式(I)所示化合物硫酸氢盐的无定形,其X-射线粉末衍射图谱的衍射角2θ在2-48°范围内没有明显特征峰。
本公开进一步提供了制备式(I)所示化合物硫酸氢盐的无定形的方法,包括步骤:a)式(I)所示化合物与乙酸乙酯,硫酸水溶液混合,b)挥发析晶。
在某些实施方式中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方式中,本公开所述的制备硫酸氢盐无定形方法还包括过滤、洗涤或干燥步骤。
本公开提供了式(I)所示化合物硫酸氢盐的A晶型,以衍射角2θ角度表示的X-射线粉末衍射图,在7.101、13.538、15.870、18.959、20.570、23.649和24.320处有特征峰。在某些实施方案中,式(I)所示化合物硫酸氢盐的A晶型在7.101、12.742、13.538、15.870、18.959、20.570、21.603、22.055、23.649和24.320处有特征峰。在某些实施方案中,式(I)所示化合物硫酸氢盐的A晶型在7.101、10.933、12.742、13.538、14.966、15.870、18.959、20.570、21.603、22.055、23.649、24.320和26.799处有特征峰。在某些实施方案中,式(I)所示化合物硫酸氢盐的A晶型以衍射角2θ角度表示的X-射线粉末衍射图谱如图10所示。
本公开进一步提供了式(I)所示化合物硫酸氢盐A晶型的方法,包括:a)式I所示化合物与甲基叔丁基醚,硫酸溶液或乙醇/水溶液混合,b)搅拌析晶。
在某些实施方案中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的 1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方案中,本公开所述的制备硫酸氢盐A晶型方法还包括过滤、洗涤或干燥等步骤。
本公开提供了式(I)所示化合物钙盐的无定形,其X-射线粉末衍射图谱的衍射角2θ在2-48°范围内没有明显特征峰。
本公开进一步提供了制备式(I)所示化合物钙盐的无定形的方法,包括步骤:a)式(I)所示化合物与丙酮,氢氧化钙溶液混合,b)挥发,固体析出。
在某些实施方式中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方式中,本公开所述的制备钙盐无定形方法还包括过滤、洗涤或干燥步骤。
本公开提供了式(I)所示化合物精氨酸盐的无定形,其X-射线粉末衍射图谱的衍射角2θ在2-48°范围内没有明显特征峰。
本公开进一步提供了制备式(I)所示化合物精氨酸盐的无定形的方法,包括步骤:a)式(I)所示化合物与乙醇/水,精氨酸溶液混合,b)挥发,固体析出。
在某些实施方式中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方式中,本公开所述的制备精氨酸盐无定形方法还包括过滤、洗涤或干燥步骤。
本公开提供了式(I)所示化合物赖氨酸盐的无定形,其X-射线粉末衍射图谱的衍射角2θ在2-48°范围内没有明显特征峰。
本公开进一步提供了制备式(I)所示化合物赖氨酸盐的无定形的方法,包括步骤:a)式(I)所示化合物与甲基叔丁基醚,赖氨酸溶液混合,b)挥发,固体析出。
在某些实施方式中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方式中,本公开所述的制备赖氨酸盐无定形方法还包括过滤、洗涤或干燥步骤。
本公开提供了式(I)所示化合物葡甲胺盐的无定形,其X-射线粉末衍射图谱的衍射角2θ在2-48°范围内没有明显特征峰。
本公开进一步提供了制备式(I)所示化合物葡甲胺盐的无定形的方法,包括步骤:a)式(I)所示化合物与丙酮,葡甲胺溶液混合,b)挥发,固体析出。
在某些实施方式中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方式中,本公开所述的制备葡甲胺盐无定形方法还包括过滤、洗涤或干燥步骤。
本公开提供了式(I)所示化合物乙醇胺盐的无定形,其X-射线粉末衍射图谱的衍射角2θ在2-48°范围内没有明显特征峰。
本公开进一步提供了制备式(I)所示化合物乙醇胺盐的无定形的方法,包括步骤:a)式(I)所示化合物与乙醇/水,乙醇胺溶液混合,b)挥发,固体析出。
在某些实施方式中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方式中,本公开所述的制备乙醇胺盐无定形方法还包括过滤、洗涤或干燥步骤。
本公开提供了式(I)所示化合物盐酸盐的无定形,其X-射线粉末衍射图谱的衍射角2θ在2-48°范围内没有明显特征峰。
本公开进一步提供了制备式(I)所示化合物盐酸盐的无定形的方法,包括步骤:a)式(I)所示化合物与乙醇/水,盐酸溶液混合,b)挥发,固体析出。
在某些实施方式中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方式中,本公开所述的制备盐酸盐无定形方法还包括过滤、洗涤或干燥步骤。
本公开提供了式(I)所示化合物酒石酸盐的无定形,其X-射线粉末衍射图谱的衍射角2θ在2-48°范围内没有明显特征峰。
本公开进一步提供了制备式(I)所示化合物酒石酸盐的无定形的方法,包括步骤:a)式(I)所示化合物与乙醇/水,酒石酸溶液混合,b)挥发,固体析出。
在某些实施方式中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方式中,本公开所述的制备酒石酸盐无定形方法还包括过滤、洗涤或干燥步骤。
本公开提供了式(I)所示化合物马来酸盐的无定形,其X-射线粉末衍射图谱的衍射角2θ在2-48°范围内没有明显特征峰。
本公开进一步提供了制备式(I)所示化合物马来酸盐的无定形的方法,包括步骤:a)式(I)所示化合物与甲基叔丁基醚,马来酸溶液混合,b)挥发,固体析出。
在某些实施方式中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方式中,本公开所述的制备马来酸盐无定形方法还包括过滤、洗涤或干燥步骤。
本公开提供了式(I)所示化合物柠檬酸盐的无定形,其X-射线粉末衍射图谱的衍射角2θ在2-48°范围内没有明显特征峰。
本公开进一步提供了制备式(I)所示化合物柠檬酸盐的无定形的方法,包括步骤:a)式(I)所示化合物与甲基叔丁基醚,柠檬酸溶液混合,b)挥发,固体析出。
在某些实施方式中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方式中,本公开所述的制备柠檬酸盐无定形方法还包括过滤、洗涤或干燥步骤。
本公开提供了式(I)所示化合物苹果酸盐的无定形,其X-射线粉末衍射图谱的衍射角2θ在2-48°范围内没有明显特征峰。
本公开进一步提供了制备式(I)所示化合物苹果酸盐的无定形的方法,包括步骤:a)式(I)所示化合物与甲基叔丁基醚,苹果酸溶液混合,b)挥发,固体析出。
在某些实施方式中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方式中,本公 开所述的制备苹果酸盐无定形方法还包括过滤、洗涤或干燥步骤。
本公开提供了式(I)所示化合物对甲苯磺酸盐的无定形,其X-射线粉末衍射图谱的衍射角2θ在2-48°范围内没有明显特征峰。
本公开进一步提供了制备式(I)所示化合物对甲苯磺酸盐的无定形的方法,包括步骤:a)式(I)所示化合物与甲基叔丁基醚,对甲苯磺酸溶液混合,b)挥发,固体析出。
在某些实施方式中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方式中,本公开所述的制备对甲苯磺酸盐无定形方法还包括过滤、洗涤或干燥步骤。
本公开提供了式(I)所示化合物甲磺酸盐的无定形,其X-射线粉末衍射图谱的衍射角2θ在2-48°范围内没有明显特征峰。
本公开进一步提供了制备式(I)所示化合物甲磺酸盐的无定形的方法,包括步骤:a)式(I)所示化合物与甲基叔丁基醚,甲磺酸溶液混合,b)挥发,固体析出。
在某些实施方式中,本公开所述溶剂所用体积(μl)可以为式I化合物质量(mg)的1-200倍,在非限制性实施方案中可以为1、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、105、110、115、120、125、130、135、140、145、150、155、160、165、170、175、180、185、190、200。在某些实施方式中,本公开所述的制备甲磺酸盐无定形方法还包括过滤、洗涤或干燥步骤。
本公开还提供了由前述式(I)所示化合物可药用盐的晶型制备得到的药物组合物。
本公开还提供了一种药物组合物,含前述可药用盐的晶型和任选自药学上可接受的载体、稀释剂或赋形剂。
本公开还提供了一种药物组合物的制备方法,包括将前述可药用盐的晶型与药学上可接受的载体、稀释剂或赋形剂混合的步骤。
本公开还提供了前述可药用盐的晶型,或前述组合物,或由前述方法制备得到的组合物在制备HIV衣壳蛋白抑制剂中的用途。
本公开还提供了前述可药用盐的晶型,或前述组合物,或由前述方法制备得到的组合物在制备用于预防和/或治疗病毒性感染疾病的药物中的用途,优选HIV感染。
本公开中所述式(I)化合物与碱分子或酸分子的化学配比测定存在一定误差,一般而言,正负10%均属于合理误差范围内。随其所用之处的上下文而有一定程度的误差变化,该误差变化不超过正负10%,正负9%、正负8%、正负7%、正负6%、正负5%、 正负4%、正负3%、正负2%、正负1%,优选正负5%。
本公开所述的“2θ或2θ角度”是指衍射角,θ为布拉格角,单位为°或度;每个特征峰2θ的误差范围为±0.20(包括超过1位小数的数字经过四舍五入后的情况),可以为-0.20、-0.19、-0.18、-0.17、-0.16、-0.15、-0.14、-0.13、-0.12、-0.11、-0.10、-0.09、-0.08、-0.07、-0.06、-0.05、-0.04、-0.03、-0.02、-0.01、0.00、0.01、0.02、0.03、0.04、0.05、0.06、0.07、0.08、0.09、0.10、0.11、0.12、0.13、0.14、0.15、0.16、0.17、0.18、0.19、0.20。
依据《中国药典》2015年版四部中“9103药物引湿性指导原则”中引湿性特征描述与引湿性增重的界定,
潮解:吸收足量水分形成液体;
极具引湿性:引湿增重不小于15%;
有引湿性:引湿增重小于15%但不小于2%;
略有引湿性:引湿增重小于2%但不小于0.2%;
无或几乎无引湿性:引湿增重小于0.2%。
本公开中所述的“差示扫描量热分析或DSC”是指在样品升温或恒温过程中,测量样品与参考物之间的温度差、热流差,以表征所有与热效应有关的物理变化和化学变化,得到样品的相变信息。
本公开中所述干燥温度一般为25℃~150℃,优选40℃~80℃,可以常压干燥,也可以减压干燥。
“药物组合物”表示含有一种或多种本文所述式(I)化合物或其可药用盐与其他化学组分的混合物,以及其他组分例如药学上接受的载体和赋形剂。药物组合物的目的是促进对生物体的给药,利于活性成分的吸收进而发挥生物活性。
本公开所述的晶型包括但不限于式(I)所示化合物的溶剂合物,所述的溶剂包括但不限于乙酸乙酯/正庚烷、乙酸异丙酯/正庚烷、甲醇/异丙醚、乙腈/异丙醚、二氯甲烷/异丙醚、乙醇/水、水/异丙醇、乙醇/正己烷、乙醇、异丙醇、二氯甲烷/正己烷、二氧六环/正己烷/异丙醚、4-甲基-2-戊酮、甲基叔丁基醚、乙醇、乙酸乙酯、乙腈、二氯甲烷、乙醇/异丙醇、乙醇/正庚烷。
本公开所述的“溶剂合物”包括但不限于式(I)化合物与溶剂结合形成的络合物。
图1:式(I)所示化合物胆碱盐无定形的XRPD图谱。
图2:式(I)所示化合物胆碱盐A晶型的XRPD图谱。
图3:式(I)所示化合胆碱盐B晶型的XRPD图谱。
图4:式(I)所示化合物钠盐I晶型的XRPD图谱。
图5:式(I)所示化合物钠盐II晶型的XRPD图谱。
图6:式(I)所示化合物钠盐III晶型的XRPD图谱。
图7:式(I)所示化合物钠盐IV晶型的XRPD图谱。
图8:式(I)所示化合物钠盐V晶型的XRPD图谱。
图9:式(I)所示化合物钾盐a晶型的XRPD图谱。
图10:式(I)所示化合物硫酸氢盐A晶型的XRPD图谱。
以下将结合实施例或实验例更详细地解释本公开,本公开中的实施例或实验例仅用于说明本公开中的技术方案,并非限定本公开中的实质和范围。
本公开中实施例中未注明具体条件的实验方法,通常按照常规条件,或按照原料或商品制造厂商所建议的条件。未注明具体来源的试剂,为市场购买的常规试剂。
化合物的结构是通过核磁共振(NMR)或/和质谱(MS)来确定的。NMR位移(δ)以10
-6(ppm)的单位给出。NMR的测定是用Bruker AVANCE-400核磁仪,测定溶剂为氘代二甲基亚砜(DMSO-d
6)、氘代氯仿(CDCl
3)、氘代甲醇(CD
3OD),内标为四甲基硅烷(TMS)。
MS的测定用Agilent 1200/1290 DAD-6110/6120 Quadrupole MS液质联用仪(生产商:Agilent,MS型号:6110/6120 Quadrupole MS)、waters ACQuity UPLC-QD/SQD(生产商:waters,MS型号:waters ACQuity Qda Detector/waters SQ Detector)、THERMO Ultimate 3000-Q Exactive(生产商:THERMO,MS型号:THERMO Q Exactive)。
高效液相色谱法(HPLC)分析使用Agilent HPLC 1200DAD、Agilent HPLC 1200VWD和Waters HPLC e2695-2489高压液相色谱仪。
手性HPLC分析测定使用Agilent 1260 DAD高效液相色谱仪。
高效液相制备使用Waters 2767、Waters 2767-SQ Detecor2、Shimadzu LC-20AP和Gilson-281制备型色谱仪。
手性制备使用Shimadzu LC-20AP制备型色谱仪。
CombiFlash快速制备仪使用Combiflash Rf200(TELEDYNE ISCO)。
薄层层析硅胶板使用烟台黄海HSGF254或青岛GF254硅胶板,薄层色谱法(TLC)使用的硅胶板采用的规格是0.15mm~0.2mm,薄层层析分离纯化产品采用的规格是0.4 mm~0.5mm。
硅胶柱色谱法一般使用烟台黄海硅胶200~300目硅胶为载体。
激酶平均抑制率及IC
50值的测定用NovoStar酶标仪(德国BMG公司)。
本公开的已知的起始原料可以采用或按照本领域已知的方法来合成,或可购买自ABCR GmbH&Co.KG,Acros Organics,Aldrich Chemical Company,韶远化学科技(Accela ChemBio Inc)、达瑞化学品等公司。
实施例中无特殊说明,反应能够均在氩气氛或氮气氛下进行。
氩气氛或氮气氛是指反应瓶连接一个约1L容积的氩气或氮气气球。
氢气氛是指反应瓶连接一个约1L容积的氢气气球。
加压氢化反应使用Parr 3916EKX型氢化仪和清蓝QL-500型氢气发生器或HC2-SS型氢化仪。
氢化反应通常抽真空,充入氢气,反复操作3次。
微波反应使用CEM Discover-S 908860型微波反应器。
实施例中无特殊说明,溶液是指水溶液。
实施例中无特殊说明,反应的温度为室温,为20℃~30℃。
实施例中的反应进程的监测采用薄层色谱法(TLC),反应所使用的展开剂,纯化化合物采用的柱层析的洗脱剂的体系和薄层色谱法的展开剂体系包括:A:正己烷/乙酸乙酯体系,B:二氯甲烷/甲醇体系,溶剂的体积比根据化合物的极性不同而进行调节,也可以加入少量的三乙胺和醋酸等碱性或酸性试剂进行调节。
本公开中实验所用仪器的测试条件:
1、差示扫描量热仪(Differential Scanning Calorimeter,DSC)
仪器型号:Mettler Toledo DSC 3+STARe System
吹扫气:氮气;氮气吹扫速度:50mL/min
升温速率:10.0℃/min
温度范围:25-350℃(或25℃-300℃)
2、X-射线粉末衍射谱(X-ray Powder Diffraction,XRPD)
仪器型号:BRUKER D8 DiscoverX-射线粉末衍射仪
扫描方式:θ/2θ,扫描范围(2θ范围):3~50°
电压:40kV,电流:40mA
3、热重分析仪(Thermogravimetric Analysis,TGA)
仪器型号:Mettler Toledo TGA2
吹扫气:氮气;氮气吹扫速度:50mL/min
升温速率:10.0℃/min
温度范围:25-400℃(或25℃-350℃)
4、DVS为动态水分吸附
检测采用SMS DVS Advantage,在25℃,湿度从0-95%,步进为10%,判断标准为每个梯度质量变化dM/dT小于0.002%,TMAX 360min,循环两圈。
5、阳离子色谱
仪器型号:美国DIONEX AQUION离子色谱仪
检测方式:电导;分离柱:IonPac CS16-CG16
淋洗液:MSA 20Mm
流速:1.0ml/min
6、阴离子色谱
仪器型号:美国DIONEX INTEGRION HPIC离子色谱仪
检测方式:电导;分离柱:DionexIonPac
TM-AS11-HC
淋洗液:EGC-500-KOH
流速:1.5ml/min
实施例1:式(I)所示化合物的制备
N-((S)-1-((R)-4-(4-氯-3-(甲磺酰胺)-1-(2,2,2-三氟乙基)-1H-吲唑-7-基)-1-(3-甲基-3-(甲磺酰基)丁-1-炔-1-基)-6,7-二氢-5H-环戊并[c]吡啶-3-基)-2-(3,5-二氟苯基)乙基)-2-((3bS,4aR)-5,5-二氟-3-(三氟甲基)-3b,4,4a,5-四氢-1H-环丙并[3,4]环戊并[1,2-c]吡唑-1-基)乙酰胺I
第一步
(1,4-二溴-6,7-二氢-5H-环戊并[c]吡啶-3-基)甲醇1b
将1,4-二溴-6,7-二氢-5H-环戊并[c]吡啶-3-羧酸乙酯1a(7.2g,20.6mmol,采用文献”Advanced Synthesis&Catalysis.2016,358,1916-1923”公知方法制备而得)溶于无水四氢呋喃(50mL),冷却到0℃,加入硼氢化锂(450mg,20.6mmol,上海国药集团化学试剂有限公司)。室温搅拌18小时。加水(80mL),乙酸乙酯(80mL×3)萃取,减压浓缩,用硅胶柱色谱法以洗脱剂体系A纯化所得残余物,得到标题产物1b(6.0g,产率:94.7%)。
MS m/z(ESI):305.9[M+1]
第二步
1,4-二溴-6,7-二氢-5H-环戊并[c]吡啶-3-甲醛1c
将草酰氯(750mg,5.91mmol,上海国药集团化学试剂有限公司)溶于二氯甲烷(20mL),冷却到-78℃,滴加入二甲基亚砜(800mg,10.2mmol,adamas)并搅拌15分钟。将化合物 1b(1.5g,4.9mmol)的二氯甲烷(10mL)溶液滴加到反应液,在-78℃下搅拌反应1小时。加入三乙胺(1.25g,12.4mmol,上海国药集团化学试剂有限公司),-78℃下搅拌反应30分钟,然后0℃下搅拌反应1.5小时。加水(30mL),二氯甲烷(30mL×2)萃取,无水硫酸氢钠干燥,减压浓缩,得到标题产物粗品1c(1.5g),产物不经纯化直接用于下一步反应。
MS m/z(ESI):303.8[M+1]
第三步
(S,Z)-N-((1,4-二溴-6,7-二氢-5H-环戊并[c]吡啶-3-基)亚甲基)-2-甲基丙烷-2-亚磺酰胺1e
将化合物1c(5.0g,16.4mmol)和(S)-2-甲基丙烷-2-亚磺酰胺1d(1.99g,16.4mmol,毕得医药科技有限公司)溶于二氯甲烷(50mL),加入碳酸铯(6.4g,19.6mmol,毕得医药科技有限公司),室温搅拌反应2小时,加水(50mL),二氯甲烷(50mL×3)萃取,减压浓缩,用硅胶柱色谱法以洗脱剂体系A纯化所得残余物,得到标题产物1e(4.5g,产率:67%)。
MS m/z(ESI):406.9[M+1]
第四步
(S)-N-(1-(1,4-二溴-6,7-二氢-5H-环戊并[c]吡啶-3-基)-2-(3,5-二氟苯基)乙基)-2-甲基丙烷-2-亚磺酰胺1f
向锌粉(1.3g,20.0mmol,上海国药集团化学试剂有限公司)的无水四氢呋喃(15mL)悬浊液中,加入一滴1,2-二溴乙烷。在加热回流状态下,再加两滴三甲基氯硅烷,剧烈搅拌回流15分钟。反应液降至0℃,加1-(溴甲基)-3,5-二氟苯(2.1g,10.0mmol,毕得医药科技有限公司)。室温搅拌4小时。将化合物1e(2.7g,6.6mmol)溶于无水N,N-二甲基甲酰胺(13mL)中,在0℃下滴加上述制得的锌试剂。室温搅拌反应16小时。加水(50mL),乙酸乙酯(50mL×3)萃取,减压浓缩,用硅胶柱色谱法以洗脱剂体系A纯化所得残余物,得到标题产物1f(2.6g,产率:75%)。
MS m/z(ESI):534.7[M+1]
第五步
1-(1,4-二溴-6,7-二氢-5H-环戊并[c]吡啶-3-基)-2-(3,5-二氟苯基)乙-1-胺盐酸盐1g
将化合物1f(2.6g,6.6mmol)溶于二氯甲烷(20mL)中,加入4M氯化氢二氧六环溶液(40mL)。室温搅拌1小时。反应液减压浓缩得到标题产物化合物1g(2.3g,产率:100%)。
MS m/z(ESI):430.8[M-35]
第六步
(1-(1,4-二溴-6,7-二氢-5H-环戊并[c]吡啶-3-基)-2-(3,5-二氟苯基)乙基)氨基甲酸叔丁酯1h
向化合物1g(2.3g,5.3mmol)的二氯甲烷(30mL)悬浊液中,加入三乙胺(3.3g,32.7mmol,上海沪试化工有限公司)和二碳酸二叔丁酯(2.4g,11.0mmol,韶远科技上海有限公司)。室温搅拌反应3小时。加水(30mL),二氯甲烷(30mL×3)萃取,减压浓缩,用硅胶柱色谱法以洗脱剂体系A纯化所得残余物,得到标题产物1h(2.1g,产率:74%)。
MS m/z(ESI):530.8[M+1]
第七步
(1-(4-溴-1-(3-甲基-3-(甲磺酰基)丁-1-炔-1-基)-6,7-二氢-5H-环戊并[c]吡啶-3-基)-2-(3,5-二氟苯基)乙基)氨基甲酸叔丁酯1j
将化合物1h(500.0mg,0.9mmol)和化合物1i(207.0mg,1.4mmol,采用专利申请”WO2018035359A1,第83页中间体im-14公开方法”制备而得)溶于N,N-二甲基甲酰胺(8mL)。加入二(三苯基膦)二氯化钯(80.0mg,0.1mmol,韶远科技上海有限公司),碘化亚铜(108.0mg,0.6mmol,上海国药集团化学试剂有限公司)和三乙胺(286.0mg,2.8mmol,上海沪试化工有限公司)。置换氮气三次,室温搅拌反应4小时。加水(20mL),乙酸乙酯(20mL×3)萃取,减压浓缩,用硅胶柱色谱法以洗脱剂体系A纯化所得残余物,得到标题产物1j(500mg,产率:89%)。
MS m/z(ESI):596.8[M+1]
第八步
(1-4-(3-氨基-4-氯-1-(2,2,2-三氟乙基)-1H-吲唑-7-基)-1-(3-甲基-3-(甲磺酰基)丁-1-炔-1-基)-6,7-二氢-5H-环戊并[c]吡啶-3-基)-2-(3,5-二氟苯基)乙基)氨基甲酸叔丁酯1l
将化合物1j(400.0mg,0.7mmol)和化合物1k(378.0mg,1mmol,采用专利申请”“WO2018035359A1,第82页中间体im-12公开方法”制备而得)溶于二氧六环(12mL)和水(2mL)。加入二叔丁基-(4-二甲基氨基苯基)膦二氯化钯(15.0mg,0.02mmol,韶远科技上海有限公司)和磷酸钾(426.0mg,2.0mmol,百灵威)。置换氮气三次,90℃搅拌反应16小时。加水(20mL),乙酸乙酯(20mL×3)萃取,减压浓缩,用硅胶柱色谱法以洗脱剂体系A纯化所得残余物,得到标题产物1l(160.0mg,产率:31%)。
MS m/z(ESI):765.8[M+1]
第九步
((S)-1-((R)-4-(4-氯-3-(N-(甲磺酰基)甲磺酰胺)-1-(2,2,2-三氟乙基)-1H-吲唑-7-基)-1-(3-甲基-3-(甲磺酰基)丁-1-炔-1-基)-6,7-二氢-5H-环戊并[c]吡啶-3-基)-2-(3,5-二氟苯基)乙基)氨 基甲酸叔丁酯1m-1
((R)-1-((S)-4-(4-氯-3-(N-(甲磺酰基)甲磺酰胺)-1-(2,2,2-三氟乙基)-1H-吲唑-7-基)-1-(3-甲基-3-(甲磺酰基)丁-1-炔-1-基)-6,7-二氢-5H-环戊并[c]吡啶-3-基)-2-(3,5-二氟苯基)乙基)氨基甲酸叔丁酯1m-2
将化合物1l(160.0mg,0.2mmol)和三乙胺(127.0mg,1.3mmol,上海沪试化工有限公司)溶于二氯甲烷(3mL),加入甲烷磺酰氯(72.0mg,0.6mmol,上海国药集团化学试剂有限公司)。室温搅拌反应1小时。加水(20mL),二氯甲烷(20mL×3)萃取,减压浓缩,用硅胶柱色谱法以洗脱剂体系A纯化所得残余物,得到消旋体。将此消旋体(170mg,0.18mmol)进行手性制备(分离条件:CHIRALPAK OD手性制备柱,5.0cm I.D.×25cmL,10μm;流动相:正己烷/异丙醇=70/30(V/V),流速:60mL/min),收集其相应组分,减压浓缩,得到标题产物1m-1(92mg,产率:48%)和1m-2(66mg,产率:34%)。
单一构型化合物1m-1:
MS m/z(ESI):921.8[M+1]
手性HPLC分析:保留时间4.471分钟,手性纯度:100%(色谱柱:CHIRALPAK OD 0.46cm I.D.×25cmL,10μm;流动相:正己烷/乙醇/二氯甲烷/二乙胺=60/30/10/0.1(V/V/V/V)。
单一构型化合物1m-2:
MS m/z(ESI):921.8[M+1]
手性HPLC分析:保留时间6.579分钟,手性纯度:100%(色谱柱:CHIRALPAK OD 0.46cm I.D.×25cmL,10μm;流动相:正己烷/乙醇/二氯甲烷/二乙胺=60/30/10/0.1(V/V/V/V)。
第十步
N-(7-((R)-3-((S)-1-氨基-2-(3,5-二氟苯基)乙基)-1-(3-甲基-3-(甲磺酰基)丁-1-炔-1-基)-6,7-二氢-5H-环戊并[c]吡啶-4-基)-4-氯-1-(2,2,2-三氟乙基)-1H-吲唑-3-基)-N-(甲磺酰基)甲磺酰胺盐酸盐1n-1
将化合物1m-1(92.0mg,0.1mmol)溶于二氯甲烷(0.5mL)中,加入4M氯化氢二氧六环溶液(3mL)。室温搅拌1小时。反应液减压浓缩得到标题产物1n-1(86mg,产率:100%)。
MS m/z(ESI):821.8[M-35]
第十一步
N-((S)-1-((R)-4-(4-氯-3-(甲磺酰胺)-1-(2,2,2-三氟乙基)-1H-吲唑-7-基)-1-(3-甲基-3-(甲磺酰基)丁-1-炔-1-基)-6,7-二氢-5H-环戊并[c]吡啶-3-基)-2-(3,5-二氟苯基)乙基)-2-((3bS,4aR)-5,5-二氟-3-(三氟甲基)-3b,4,4a,5-四氢-1H-环丙并[3,4]环戊并[1,2-c]吡唑-1-基)乙酰胺I
将化合物1n-1(86.0mg,0.1mmol),化合物1o(29.0mg,0.1mmol,采用专利申请”“WO2018035359A1,第80页中间体im-8a公开方法”制备而得)和2-(7-氧化苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸盐(50.0mg,0.13mmol,上海国药集团化学试剂有限公司)溶于N,N-二甲基甲酰胺(2mL)中,加入N,N-二异丙基乙胺(65.0mg,0.5mmol,adamas)。室温搅拌1小时。加入2N氢氧化钠(0.3mL),室温搅拌1小时。加水(10mL),乙酸乙酯(10mL×3)萃取,减压浓缩,用高效液相色谱法纯化(Sharpsil-T C18 150*30mm,5μm,洗脱体系:H
2O(0.1%三氟乙酸)、乙腈),得到标题产物I(33mg,产率:30%)。
MS m/z(ESI):1007.5[M+1]
1H NMR(400MHz,CD
3OD)δ7.20(d,1H),6.76(t,1H),6.49(d,1H),6.26(d,2H),4.92-4.75(m,3H),4.66-4.59(m,1H),4.01-3.95(m,1H),3.24(s,3H),3.23(s,3H),3.17-3.13(m,2H),3.05-3.00(m,1H),2.91-2.86(m,1H),2.82-2.74(m,1H),2.57-2.41(m,3H),2.18-2.15(m,1H),2.07-1.99(m,1H),1.83(s,6H),1.45-1.40(m,1H),1.09(s,1H)。
生物学评价
测试例1、式(I)化合物对体外HIV-1衣壳蛋白多聚的影响
一、实验材料及仪器
1.MAb Anti GST-Eu cryptate(Cisbio)
2.MAb Anti 6HIS-XL665(Cisbio)
3.His标签HIV-1衣壳蛋白(以下称His-CA)
4.GST标签HIV-1衣壳蛋白(以下称GST-CA)
5. 384-well non-binding surface microplate,white(Corning)
6.酶标仪(BMG)
二、实验步骤
HIV-1衣壳蛋白在高盐溶液中会自发聚集。将来源于HIV-1 NL4-3毒株的衣壳蛋白用6His标签和GST标签分别标记表达,并纯化。在高盐浓度下,混合His-CA和GST-CA,用带Eu3+-Cryptate(能量供体)标记的GST抗体和带XL665(能量受体)标记的His抗体,去检测衣壳蛋白的多聚水平。由于Eu3+-Cryptate的发射光谱与XL665的激发光谱重叠,当带两种标签的衣壳蛋白形成多聚复合物,可以使能量供体和能量受体拉到足够近的距离,能量供体在外来光源激发(例如氙灯或激光)下,捕获的能量部分释放,发射波长为620nM,部分共振转移到能量受体上使其激发,发射波长为665nM产生光信号,其信号强度与标签蛋白多聚化程度呈正比例。
在干净的管子中用蛋白稀释液(50mM Tris-HCl,pH8.0,50mM NaCl,0.4mM MgCl
2,0.05%Triton X-100,2%甘油)稀释His-CA至2μM,同时加入终浓度为260nM的MAb Anti 6HIS-XL665;在另一个干净的管子中用蛋白稀释液稀释GST-CA至20nM,同时加入终浓度为3.33nM的MAb Anti GST-Eu cryptate,冰上孵育半小时。化合物先用DMSO配制成20mM,再用DMSO稀释至首个浓度2mM,并以5倍依次稀释成8个浓度,设置对照的孔加入DMSO,系列稀释的化合物再用蛋白稀释液稀释20倍成10倍工作浓度。配制2倍浓度衣壳蛋白多聚反应液:50mM Tris-HCl,pH8.0,1M NaCl,800mM KF;在预冷的白色圆底384孔板中,加入4μl His-CA-His抗体混合物,4μl GST-CA-GST抗体混合物,2μl 10倍浓度的化合物,10μl 2倍浓度衣壳蛋白多聚反应液,混匀后将板子用避光封板膜密封,反应板置于37度培养箱孵育2个小时。孵育后用337nM激发光激发样品,检测收集620nM和665nM信号值,根据信号值计算Ratio值=(信号665nM/信号620nM)*10000。用Graphpad Prism软件根据化合物各浓度与相应的Ratio值计算化合物的EC
50值。
式(I)化合物通过对HIV-1衣壳蛋白多聚抑制,测得的EC
50值见下表:
实施例编号 | EC 50(nM) | Emax(%) |
式(I)化合物 | 9 | 100 |
结论:式(I)化合物对HIV-1衣壳蛋白的多聚具有明显的抑制作用。
实施例2:胆碱盐无定形的制备
将式(I)所示化合物(1.00g)溶于异丙醇(15mL)中,加入氢氧化胆碱(268mg,47%水溶液)后室温反应,得黄色溶液,浓缩反应液至干,再加入10mL二氯甲烷溶清后再浓缩,真空干燥得到产物(1.1g,收率:99.79%)。经X-射线粉末衍射仪检测,该产物为无定形,XRPD谱图如图1所示。
所得产物的核磁(HNMR)检测结果:该盐中式(I)化合物与胆碱成盐摩尔比约为1:1。
1H NMR(500MHz,DMSO-d
6)δ9.00(d,J=8.4Hz,1H),6.99(t,J=9.4Hz,1H),6.94(d,J=7.6Hz,1H),6.69(d,J=7.6Hz,1H),6.41(d,J=6.3Hz,2H),5.36(s,1H),4.89(d,J=16.5Hz,1H),4.78–4.69(m,2H),4.09(dd,J=16.1,8.7Hz,1H),3.84(s,3H),3.42–3.38(m,2H),3.25(s,3H),3.10(s,9H),3.05(t,J=7.9Hz,2H),2.93–2.80(m,2H),2.77(s,3H),2.67–2.53(m,3H),2.40(ddd,J=17.3,8.6,4.8Hz,1H),2.09–2.01(m,1H),1.93(dt,J=12.5,8.3Hz,1H),1.74(d,J=5.5Hz,6H),1.39(q,J=7.1Hz,1H),0.98–0.92(m,1H)。
实施例3:胆碱盐无定形的制备
称取游离态式(I)所示化合物10mg,加入0.2mL甲基叔丁基醚,溶清后加入2.8μl 44%氢氧化胆碱水溶液,室温打浆,加入1.4mL正庚烷,析出固体,固体真空干燥,得到产物。经X-射线粉末衍射仪检测,该产物为无定形。
实施例4:胆碱盐晶型A的制备
将式(I)所示化合物的胆碱盐无定形(120mg)加入到1mL二氧六环、正己烷和异丙醚(V/V/V=2:1:1)混合溶剂中,溶解(或溶清),室温搅拌析出固体,固体真空干燥,得到产物。经X-射线粉末衍射仪检测,将该产物定义为晶型A,XRPD谱图如图2所示,其特征峰位置如表1所示。
表1
实施例5:胆碱盐晶型A的制备
将式(I)所示化合物的胆碱盐无定形(60mg)加入到0.5mL 4-甲基-2-戊酮中,溶清,室温搅拌析出固体,固体真空干燥,得到产物。经X-射线粉末衍射仪检测,该产物为晶型A。
实施例6:胆碱盐晶型B的制备
将式(I)所示化合物(740mg)和氢氧化胆碱(198mg,47%水溶液)加入到异丙醇中,室温搅拌,过滤,滤饼真空干燥,得到产物。经X-射线粉末衍射仪检测,将该产物定义为晶型B,XRPD谱图如图3所示,其特征峰位置如表2所示。DSC谱图显示,吸热峰峰值65.75℃,178.03℃。TGA谱图显示,25℃-150℃失重1.06%。
表2
实施例7:胆碱盐晶型B的制备
将式(I)所示化合物1g,加入10mL乙醇溶清后,加入0.28mL氢氧化胆碱(44%wt) 反应,室温下缓慢滴加正庚烷40mL,析出固体,固体真空干燥,得到产物。经X-射线粉末衍射仪检测,该产物为晶型B。
实施例8:胆碱盐晶型B的制备
称取式(I)所示化合物的胆碱盐无定形(60mg),缓慢加入0.5mL甲醇和异丙醚(V/V=1:1)的混合溶剂,溶清,室温搅拌,析出固体,固体真空干燥得到产物,得到产物。经X-射线粉末衍射仪检测,该产物为晶型B。
实施例9:胆碱盐晶型B的制备
称取式(I)所示化合物的胆碱盐无定形(60mg),缓慢加入0.5mL异丙醇,溶清,室温搅拌,析出固体,固体干燥得到产物,得到产物。经X-射线粉末衍射检测,该产物为晶型B。
实施例10:胆碱盐晶型B的制备
称取式(I)所示化合物的胆碱盐无定形(60mg,),加入1.5mL二氯甲烷和异丙醚(V/V=2:1)混合溶剂,室温打浆,析出固体,固体真空干燥,得到产物。经X-射线粉末衍射仪检测,该产物为晶型B。
实施例11:胆碱盐晶型B的制备
将式(I)所示化合物的胆碱盐无定形(120mg)加入到1mL纯水和异丙醇(V/V=10:1)混合溶剂,室温打浆,析出固体,固体真空干燥,得到产物。经X-射线粉末衍射仪检测,该产物为晶型B。
实施例12:胆碱盐B晶型的制备
将式(I)所示化合物的胆碱盐的A晶型35mg,加入0.5ml异丙醇,打浆固体析出,固体真空干燥,得到产物。经X-射线粉末衍射仪检测,该产物为晶型B。
实施例13:胆碱盐B晶型的制备
将式(I)所示化合物的胆碱盐晶型A(35mg)加入到0.5mL二氯甲烷和正己烷(V/V=1:1)混合溶剂中,室温打浆析出固体,固体真空干燥,得到产物。经X-射线粉末衍射仪 检测,该产物为晶型B。
实施例14:钠盐无定形的制备
式(I)所示化合物10mg,加入0.2mL乙酸乙酯,溶清后加入2.6μl 4mol/L氢氧化钠水溶液,室温打浆,加入1.2mL正庚烷,析出固体,固体真空干燥,得到产物。经X-射线粉末衍射仪检测,该产物为无定形。
实施例15:钠盐晶型I的制备
式(I)所示化合物10mg,加入0.1mL甲基叔丁基醚,加入5.45μL的2mol/L氢氧化钠水溶液,在5℃-50℃范围内升降温搅拌,析出固体,固体真空干燥,得到产物。离子色谱检测其钠离子含量为2.13%,式(I)所示化合物与钠离子的物质的量比为1:1。经X-射线粉末衍射仪检测,将该产物定义为晶型I,XRPD谱图如图4所示,其特征峰位置如表3所示。DSC谱图显示,吸热峰峰值131.81℃、278.05℃。TGA谱图显示,25℃-185℃失重3.81%。
表3
实施例16:钠盐晶型I的制备
式(I)所示化合物钠盐晶型III 10mg,加入1mL甲基叔丁基醚(MTBE),打浆后固 体析出,固体真空干燥,得到产物。经X-射线粉末衍射仪检测,该产物为晶型I。
实施例17:钠盐晶型II的制备
式(I)所示化合物200mg,加入4.0mL甲基叔丁基醚(MTBE),加入氢氧化钠溶液(19.84mg氢氧化钠溶于0.05mL水中),室温搅拌,析出固体后,固体真空干燥,得到产物。经X-射线粉末衍射仪检测,将该产物定义为晶型II,XRPD谱图如图5所示,其特征峰位置如表4所示。DSC谱图显示,吸热峰峰值278.1℃。TGA谱图显示,25℃-150℃失重0.92%。
表4
实施例18:钠盐II晶型的制备
式(I)所示化合物钠盐的晶型I加热至160℃,并恒温保持1分钟后降至室温,得到固体产物。经X-射线粉末衍射仪检测,该产物为晶型II。
实施例19:钠盐II晶型的制备
式(I)所示化合物100mg,加入1.0mL异丙醇,加入氢氧化钠溶液(4.36mg氢氧化钠溶于0.025mL水中),室温下搅拌,加入2mL正庚烷打浆,析出固体,固体真空干燥,得到产物。经X-射线粉末衍射仪检测,该产物为晶型II。
实施例20:钠盐III晶型的制备
式(I)所示化合物2g,加入20mL异丙醇,加入氢氧化钠溶液(83.32mg氢氧化钠溶于0.2mL水中),室温下搅拌,析出固体,固体真空干燥,得到产物。经X-射线粉末衍射仪检测,将该产物定义为晶型III,离子色谱检测其钠离子含量为2.12%,式(I)所示化合物与钠离子的物质的量比为1:1。XRPD谱图如图6所示,其特征峰位置如表5所示。DSC谱图显示,吸热峰峰值299.93℃。TGA谱图显示,25℃-240℃失重0.15%。
表5
实施例21:钠盐IV晶型的制备
式(I)所示化合物500mg,加入8.0mL乙醇,加入氢氧化钠溶液(20.83mg氢氧化钠溶于0.1mL水中),在10℃-40℃范围内升降温,析出固体,固体真空干燥,得到产物。经X-射线粉末衍射仪检测,将该产物定义为晶型IV,XRPD谱图如图7所示,其特征峰位置如表6所示。DSC谱图显示,吸热峰峰值298.70℃。TGA谱图显示,25℃-205℃失重0.35%。
表6
实施例22:钠盐V晶型的制备
式(I)所示化合物2g,加入20mL异丙醇,加入氢氧化钠溶液(83.32mg氢氧化钠溶于0.2mL水中),室温下搅拌,析出固体,固体真空干燥,得到产物。经X-射线粉末衍射仪检测,将该产物定义为晶型V,XRPD谱图如图8所示,其特征峰位置如表7所示。DSC谱图显示,吸热峰峰值114.14℃,293.92℃。TGA谱图显示,25℃-170℃失重5.12%。
表7
实施例23:钠盐V晶型的制备
5mg式(I)所示化合物钠盐的晶型II或晶型III或晶型IV,或其中两种或三种晶型的混合物,加入1mL异丙醚,室温或50℃下打浆析出固体,固体真空干燥,得到产物。经X-射线粉末衍射仪检测,该产物为晶型V。
实施例24:钠盐V晶型的制备
5mg式(I)所示化合物钠盐的晶型III,加入1mL异丙醇,室温下或50℃下打浆 析出固体,固体真空干燥,得到产物。经X-射线粉末衍射仪检测,该产物为晶型V。
实施例25:钾盐无定形的制备
式(I)所示化合物10mg,加入0.1mL丙酮溶清后,加入5.45μL的2mol/L氢氧化钾水溶液后搅拌,溶液保持澄清,室温下缓慢挥发,得到固体粉末产物。经X-射线粉末衍射仪检测,该产物为无定形。
实施例26:钾盐a晶型的制备
式(I)所示化合物10mg,加入0.1mL甲基叔丁基醚,加入5.45μL的2mol/L氢氧化钾水溶液,搅拌析出固体,离心,固体真空干燥,得到产物。离子色谱检测其钾离子含量为3.42%,式(I)所示化合物与钠离子的物质的量比为1:1。经X-射线粉末衍射仪检测,将该产物定义为晶型a,XRPD谱图如图9所示,其特征峰位置如表8所示。
表8
实施例27:硫酸氢盐无定形的制备
式(I)所示化合物10mg,加入1mL乙酸乙酯,溶清后加入5.45μL的2mol/L硫酸水溶液后搅拌,溶液保持澄清,室温下缓慢挥发,得到固体粉末产物。经X-射线粉末衍射仪检测,该产物为无定形。
实施例28:硫酸氢盐A晶型的制备
式(I)所示化合物10mg,加入0.1mL甲基叔丁基醚,加入5.45μL的2mol/L硫酸水溶液,搅拌析出固体,离心,固体真空干燥,得到产物。通过单晶结构解析式(I) 所示化合物与硫酸氢根离子的物质的量比为1:1。经X-射线粉末衍射仪检测,将该产物定义为晶型A,XRPD谱图如图10所示,其特征峰位置如表9所示。
表9
实施例29:钙盐无定形的制备
式(I)所示化合物10mg,加入1mL丙酮,溶清后加入0.81mg氢氧化钙后,溶液 保持澄清,室温下缓慢挥发,得到固体粉末产物。经X-射线粉末衍射仪检测,该产物为无定形。
实施例30:精氨酸盐无定形的制备
式(I)所示化合物10mg,加入1mL乙醇/水(V/V,95:5),溶清后加入10.91μL的1mol/L精氨酸盐溶液后,溶液保持澄清,室温下缓慢挥发,得到固体粉末产物。经X-射线粉末衍射仪检测,该产物为无定形。
实施例31:赖氨酸盐无定形的制备
式(I)所示化合物10mg,加入1mL甲基叔丁基醚,溶清后加入10.91μL的1mol/L赖氨酸溶液后,溶液保持澄清,室温下缓慢挥发,得到固体粉末产物。经X-射线粉末衍射仪检测,该产物为无定形。
实施例32:葡甲胺盐无定形的制备
式(I)所示化合物10mg,加入1mL丙酮,溶清后加入10.91μL的1mol/L葡甲胺溶液后,溶液保持澄清,室温下缓慢挥发,得到固体粉末产物。经X-射线粉末衍射仪检测,该产物为无定形。
实施例33:乙醇胺盐无定形的制备
式(I)所示化合物10mg,加入1mL乙醇/水(V/V,95:5),溶清后加入6.61μL的1.65mol/L乙醇胺溶液后,溶液保持澄清,室温下缓慢挥发,得到固体粉末产物。经X-射线粉末衍射仪检测,该产物为无定形。
实施例34:盐酸盐无定形的制备
式(I)所示化合物10mg,加入1mL乙醇/水(V/V,95:5),溶清后加入5.45μL的2 mol/L盐酸溶液后,溶液保持澄清,室温下缓慢挥发,得到固体粉末产物。经X-射线粉末衍射仪检测,该产物为无定形。
实施例35:酒石酸盐无定形的制备
式(I)所示化合物10mg,加入1mL乙醇/水(V/V,95:5),溶清后加入10.91μL的1mol/L酒石酸溶液后,溶液保持澄清,室温下缓慢挥发,得到固体粉末产物。经X-射线粉末衍射仪检测,该产物为无定形。
实施例36:马来酸盐无定形的制备
式(I)所示化合物10mg,加入1mL甲基叔丁基醚,溶清后加入10.91μL的1mol/L马来酸溶液后,溶液保持澄清,室温下缓慢挥发,得到固体粉末产物。经X-射线粉末衍射仪检测,该产物为无定形。
实施例37:柠檬酸盐无定形的制备
式(I)所示化合物10mg,加入1mL甲基叔丁基醚,溶清后加入10.91μL的1mol/L柠檬酸溶液后,溶液保持澄清,室温下缓慢挥发,得到固体粉末产物。经X-射线粉末衍射仪检测,该产物为无定形。
实施例38:苹果酸盐无定形的制备
式(I)所示化合物10mg,加入1mL甲基叔丁基醚,溶清后加入10.91μL的1mol/L苹果酸溶液后,溶液保持澄清,室温下缓慢挥发,得到固体粉末产物。经X-射线粉末衍射仪检测,该产物为无定形。
实施例39:对甲苯磺酸盐无定形的制备
式(I)所示化合物10mg,加入1mL甲基叔丁基醚,溶清后加入10.91μL的1mol/L 对甲苯磺酸溶液后,溶液保持澄清,室温下缓慢挥发,得到固体粉末产物。经X-射线粉末衍射仪检测,该产物为无定形。
实施例40:甲磺酸盐无定形的制备
式(I)所示化合物10mg,加入1mL甲基叔丁基醚,溶清后加入10.91μL的1mol/L甲磺酸溶液后,溶液保持澄清,室温下缓慢挥发,得到固体粉末产物。经X-射线粉末衍射仪检测,该产物为无定形。
实施例41:式(I)所示化合物不同盐晶型的引湿性研究
采用Surface Measurement Systems advantage,在25℃,湿度从50%起,考察湿度范围为0%-95%,步进为10%,判断标准为每个梯度质量变化dM/dT小于0.002%,TMAX360min,循环两圈。分别考察式I所示化合物不同盐晶型的引湿性,实验结果如表10:
表10:式I所示化合物不同盐晶型的引湿性
供试品 | 0.0%RH-95.0%RH | 20.0%RH-80.0%RH | 晶型 |
硫酸氢盐晶型A | 4.55% | 1.59%(略有引湿性) | 不变 |
钠盐晶型II | 34.16% | 11.61%(有引湿性) | 不变 |
钠盐晶型III | 2.04% | 0.73%(略有引湿性) | 不变 |
钠盐晶型IV | 1.03% | 0.45%(略有引湿性) | 转变 |
钾盐晶型a | 8.77% | 2.86%(有引湿性) | 不变 |
胆碱盐晶型B | 9.92% | 5.96%(有引湿性) | 不变 |
实施例42:式I所示化合物不同盐晶型的影响因素稳定性研究
将式(I)所示化合物硫酸氢盐晶型A、钠盐晶型II、钠盐晶型III、钾盐晶型a和胆碱盐晶型B分别敞口平摊放置,分别考察在高温(40℃、60℃)、高湿(RH 75%、RH 92.5%)条件下样品的稳定性,取样考察期为30天,实验结果分别如表11-15所示:
表11
结果表明:40℃、60℃、75%RH和92.5%RH下,式I化合物硫酸氢盐的A晶型晶型未转变,物理稳定性良好。除高温(60℃)条件外,40℃、75%RH、92.5%RH条件下化学稳定性良好。
表12
结果表明:40℃、60℃、75%RH和92.5%RH条件下,式I化合物钠盐的II晶型未 转变,物理和化学稳定性良好。
表13
结果表明:40℃、60℃、75%RH和92.5%RH下,式I化合物钠盐的III晶型未转变,物理和化学稳定性良好。
表14
结果表明:40℃、60℃、75%RH和92.5%RH条件下,式I所示化合物钾盐的a晶型未转变,物理和化学稳定性良好。
表15
结果表明:40℃、60℃、75%RH和92.5%RH条件下式(I)所示化合物胆碱盐的B晶型物理和化学稳定性良好。
实验例43:式I所示化合物不同盐晶型的长期/加速稳定性
将式I所示化合物硫酸氢盐A晶型、钠盐II晶型、钠盐III晶型、钾盐a晶型和胆碱盐晶型B,分别放置4℃,25℃,60%RH和40℃,75%RH条件考察其稳定性,实验结果如表16-20所示。
表16:硫酸氢盐A晶型的长期/加速稳定性
表17:钠盐II晶型的长期/加速稳定性
表18:钠盐III晶型的长期/加速稳定性
表19:钾盐a晶型的长期/加速稳定性
表20:胆碱盐B晶型的长期/加速稳定性
长期/加速稳定性实验显示:式(I)所示化合物的硫酸氢盐A晶型、钠盐II晶型、钠盐III晶型、钾盐a晶型和胆碱盐B晶型长期加速稳定性条件下放置6个月均具有较好的物理、化学稳定性。
Claims (15)
- 根据权利要求1所述的可药用盐,其特征在于,所述式(I)所示化合物与碱分子或酸分子的化学配比为1:0.5~1:3,优选1:0.5、1:1、1:2或1:3,最优选1:1或1:2。
- 制备权利要求1或2所述的可药用盐的方法,包括:式(1)所述化合物与酸或碱成盐的步骤。
- 式(I)所示化合物胆碱盐的B晶型,其特征在于,以衍射角2θ角度表示的X-射线粉末衍射图,在8.056、10.761、14.170、14.835、20.657、22.751和27.938处有特征峰,优选在8.056、10.761、12.289、14.170、14.835、20.657、21.279、21.944、22.751和27.938处有特征峰,更优选在8.056、10.761、12.289、14.170、14.835、17.676、20.657、21.279、21.944、22.751、25.061、27.938和29.791处有特征峰,最优选以衍射角2θ角度表示的X-射线粉末衍射图谱如图3所示。
- 式(I)所示化合物钠盐的I晶型,其特征在于,以衍射角2θ角度表示的X-射线粉末衍射图,在5.167、5.869、10.671、17.850、19.388、22.646和27.604处有特征峰,优选在5.167、5.869、10.671、16.031、17.850、18.677、19.388、22.646、24.974和27.604处有特征峰,更优选在5.167、5.869、9.409、10.671、12.035、16.031、17.850、18.677、19.388、21.811、22.646、23.483、24.974和27.604处有特征峰,最优选以衍射角2θ角度表示的X-射线粉末衍射图谱如图4所示。
- 式(I)所示化合物钠盐的II晶型,其特征在于,以衍射角2θ角度表示的X-射线粉末衍射图,在5.293、6.788、10.864、17.477、18.966、20.950和23.653处有特征峰,优选在5.293、6.788、10.864、16.027、17.477、18.966、20.950、22.115、23.653和27.156处有特征峰,更优选在5.293、5.561、6.788、10.864、11.332、13.181、16.027、17.477、18.966、20.950、22.115、23.653、24.509、25.979和27.156处有特征峰,最优选以衍射角2θ角度表示的X-射线粉末衍射图谱如图5所示。
- 式(I)所示化合物钠盐的III晶型,其特征在于,以衍射角2θ角度表示的X-射线粉末衍射图,在6.352、8.913、12.297、18.141、18.585、19.373和20.718处有特征峰,优选在6.352、8.913、12.297、18.141、18.585、19.373、20.718、21.216、21.938和26.014处有特征峰,更优选在6.352、8.913、12.297、14.919、16.346、18.141、18.585、19.373、20.718、21.216、21.938、26.014和27.864处有特征峰,最优选以衍射角2θ角度表示的X-射线粉末衍射图谱如图6所示。
- 根据权利要求4-10中任意一项所述的晶型,其特征在于,所述2θ角误差范围为±0.20。
- 一种药物组合物,含有权利要求1或2所述的可药用盐,或权利要求4-11中任意一项所述的晶型和任选自药学上可接受的载体、稀释剂或赋形剂。
- 一种药物组合物的制备方法,包括将权利要求1或2所述的可药用盐,或权利要求4-11中任意一项所述的晶型与药学上可接受的载体、稀释剂或赋形剂混合的步骤。
- 权利要求1或2所述的可药用盐,权利要求4-11中任意一项所述的晶型,或权利要求12所述的组合物,或由权利要求13所述方法制备得到的组合物在制备HIV衣壳蛋白抑制剂中的用途。
- 权利要求1或2所述的可药用盐,权利要求4-11中任意一项所述的晶型,或权利要求12所述的组合物,或由权利要求13所述方法制备得到的组合物在制备用于预防 和/或治疗病毒性感染疾病的药物中的用途,优选HIV感染。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22810666.2A EP4361140A1 (en) | 2021-05-28 | 2022-05-27 | Pharmaceutically acceptable salt and crystal form of fused pyridine ring derivative and preparation method therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110589463.6 | 2021-05-28 | ||
CN202110589463 | 2021-05-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022247942A1 true WO2022247942A1 (zh) | 2022-12-01 |
Family
ID=84229514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/095748 WO2022247942A1 (zh) | 2021-05-28 | 2022-05-27 | 一种稠合吡啶环衍生物的可药用盐、晶型及其制备方法 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4361140A1 (zh) |
TW (1) | TW202313584A (zh) |
WO (1) | WO2022247942A1 (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013006738A1 (en) * | 2011-07-06 | 2013-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
WO2014110297A1 (en) * | 2013-01-09 | 2014-07-17 | Gilead Sciences, Inc. | (hetero) arylacetamide derivatives as antiretroviral agents |
CN105705500A (zh) * | 2013-03-01 | 2016-06-22 | 吉利德科学公司 | 用于治疗hiv的酰胺化合物 |
WO2018035359A1 (en) | 2016-08-19 | 2018-02-22 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
CN111051296A (zh) * | 2017-08-17 | 2020-04-21 | 吉利德科学公司 | Hiv衣壳抑制剂的固体形式 |
WO2021104413A1 (zh) | 2019-11-29 | 2021-06-03 | 江苏恒瑞医药股份有限公司 | 稠合吡啶环衍生物、其制备方法及其在医药上的应用 |
-
2022
- 2022-05-27 TW TW111119952A patent/TW202313584A/zh unknown
- 2022-05-27 WO PCT/CN2022/095748 patent/WO2022247942A1/zh unknown
- 2022-05-27 EP EP22810666.2A patent/EP4361140A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013006738A1 (en) * | 2011-07-06 | 2013-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
WO2014110297A1 (en) * | 2013-01-09 | 2014-07-17 | Gilead Sciences, Inc. | (hetero) arylacetamide derivatives as antiretroviral agents |
CN105705500A (zh) * | 2013-03-01 | 2016-06-22 | 吉利德科学公司 | 用于治疗hiv的酰胺化合物 |
WO2018035359A1 (en) | 2016-08-19 | 2018-02-22 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
CN109890808A (zh) * | 2016-08-19 | 2019-06-14 | 吉利德科学公司 | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 |
CN111051296A (zh) * | 2017-08-17 | 2020-04-21 | 吉利德科学公司 | Hiv衣壳抑制剂的固体形式 |
WO2021104413A1 (zh) | 2019-11-29 | 2021-06-03 | 江苏恒瑞医药股份有限公司 | 稠合吡啶环衍生物、其制备方法及其在医药上的应用 |
Non-Patent Citations (6)
Title |
---|
"9103 Guiding principles for drug hygroscopicity", vol. 4, 2015, CHINESE PHARMACOPOEIA |
"Advanced Synthesis & Catalysis", vol. 358, 2016, pages: 1916 - 1923 |
ENGELMAN, A.CHEREPANOV, P., NATURE REVIEWS, vol. 10, 2012, pages 279 - 290 |
FLEXNER, C., NATURE REV DRUG DISCOV, vol. 6, 2007, pages 959 - 966 |
GRANT, R. M.HECHT, F. M.WARMERDAM, M., JAMA, vol. 288, no. 181, 2002, pages 188 - 559 |
SMITH, R. J.OKANO, J. T.KAHN, J. S.BODINE, E. N.BLOWER, S., SCIENCE, vol. 327, 2010, pages 697 - 701 |
Also Published As
Publication number | Publication date |
---|---|
EP4361140A1 (en) | 2024-05-01 |
TW202313584A (zh) | 2023-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11753406B2 (en) | Salts of a PD-1/PD-L1 inhibitor | |
US11760756B2 (en) | Crystalline form of a PD-1/PD-L1 inhibitor | |
JP6059723B2 (ja) | 4−(8−メトキシ−1−((1−メトキシプロパン−2−イル)−2−(テトラヒドロ−2H−ピラン−4−イル)−1H−イミダゾ[4,5−c]キノリン−7−イル)−3,5−ジメチルイソオキサゾールおよびブロモドメイン阻害剤としてのその使用 | |
EP3558973A1 (en) | Pyridine derivatives as immunomodulators | |
BR112020019700A2 (pt) | Compostos heterocíclicos como imunomoduladores | |
WO2018119236A1 (en) | Triazolo[1,5-a]pyridine derivatives as immunomodulators | |
CA3200844A1 (en) | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof | |
TWI675839B (zh) | 一種jak激酶抑制劑的硫酸氫鹽的結晶形式及其製備方法 | |
WO2020233641A1 (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
JP6779867B2 (ja) | ピリミジン化合物およびその使用方法 | |
JP7430656B2 (ja) | Cdk4/6活性阻害化合物の結晶形およびその使用 | |
WO2017220007A1 (zh) | 作为egfr抑制剂的苯胺嘧啶化合物的结晶 | |
CN112047893A (zh) | 吉非替尼与水杨酸共晶体 | |
CN117295742A (zh) | 化合物ⅰ的新形式及它们的应用 | |
WO2020061996A1 (zh) | 氘代azd9291化合物的新晶型及其用途 | |
JP4980431B2 (ja) | 抗ウイルス剤のマレイン酸モノ塩及びそれを含有する医薬組成物 | |
WO2022247942A1 (zh) | 一种稠合吡啶环衍生物的可药用盐、晶型及其制备方法 | |
US11299462B2 (en) | Crystal form of oxopicolinamide derivative and preparation method therefor | |
WO2022179577A1 (zh) | 一种环丙基取代的苯并呋喃类化合物的晶型及其制备方法 | |
TW201922690A (zh) | 環-amp反應元素結合蛋白的抑制劑 | |
WO2019080865A1 (zh) | 一种炔基吡啶类脯氨酰羟化酶抑制剂的晶型及其制备方法 | |
WO2019154273A1 (zh) | 喹啉衍生物的结晶 | |
CN115403559A (zh) | 一种稠合吡啶环衍生物的晶型及其制备方法 | |
WO2023093861A1 (zh) | Axl激酶抑制剂的单对甲苯磺酸盐及其晶型 | |
WO2024078618A1 (zh) | 一种含氰基取代的多肽类化合物的晶型及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22810666 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022810666 Country of ref document: EP Effective date: 20240102 |